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Abstract
The Concise Guide to PHARMACOLOGY 2021/22 is the ﬁfth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly
1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and
links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/
doi/bph.15541. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ion channels, nuclear hormone
receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for
further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2021, and supersedes data presented in the 2019/20,
2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International
Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
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Overview: Catalytic receptors are cell-surface proteins, usually
dimeric in nature, which encompass ligand binding and
functional domains in one polypeptide chain. The ligand
binding domain is placed on the extracellular surface of the
plasma membrane and separated from the functional domain by
a single transmembrane-spanning domain of 20-25 hydrophobic
amino acids. The functional domain on the intracellular face of
the plasma membrane has catalytic activity, or interacts with
particular enzymes, giving the superfamily of receptors its name.
Endogenous agonists of the catalytic receptor superfamily are
peptides or proteins, the binding of which may induce
dimerization of the receptor, which is the functional version of
the receptor.
Amongst the catalytic receptors, particular subfamilies may be
readily identiﬁed dependent on the function of the enzymatic

portion of the receptor. The smallest group is the particulate
guanylyl cyclases of the natriuretic peptide receptor family. The
most widely recognized group is probably the receptor tyrosine
kinase (RTK) family, epitomized by the neurotrophin receptor
family, where a crucial initial step is the activation of a signalling
cascade by autophosphorylation of the receptor on intracellular
tyrosine residue(s) catalyzed by enzyme activity intrinsic to the
receptor. A third group is the extrinsic protein tyrosine kinase
receptors, where the catalytic activity resides in a separate
protein from the binding site. Examples of this group include the
GDNF and ErbB receptor families, where one, catalytically silent,
member of the heterodimer is activated upon binding the ligand,
causing the second member of the heterodimer, lacking ligand
binding capacity, to initiate signaling through tyrosine
phosphorylation. A fourth group, the receptor threonine/serine

kinase (RTSK) family, exempliﬁed by TGF-β and BMP receptors,
has intrinsic serine/threonine protein kinase activity in the
heterodimeric functional unit. A ﬁfth group is the receptor
tyrosine phosphatases (RTP), which appear to lack cognate
ligands, but may be triggered by events such as cell:cell contact
and have identiﬁed roles in the skeletal, hematopoietic and
immune systems.
A further group of catalytic receptors for the Guide is the
integrins, which have roles in cell:cell communication, often
associated with signaling in the blood.

Family structure

S265
S266
S268
S268
S270
S271
S272
S273
S274
S275
–

Cytokine receptor family
IL-2 receptor family
IL-3 receptor family
IL-6 receptor family
IL-12 receptor family
Prolactin receptor family
Interferon receptor family
IL-10 receptor family
Immunoglobulin-like family of IL-1 receptors
IL-17 receptor family
Fc epsilon receptors

S276
–

GDNF receptor family
Immune checkpoint catalytic receptors

S277
S281
S281
S283
S285
S285
S286
S287

Integrins
Pattern recognition receptors
Toll-like receptor family
NOD-like receptor family
RIG-I-like receptor family
Receptor guanylyl cyclase (RGC) family
Transmembrane guanylyl cyclases
Nitric oxide (NO)-sensitive (soluble) guanylyl
cyclase

–
–
S288
S289
S290
S291
S292
S293
S294
S294
S295
S296
S296
S297
S297

Receptor kinases
TK: Tyrosine kinase
Receptor tyrosine kinases (RTKs)
Type I RTKs: ErbB (epidermal growth
factor) receptor family
Type II RTKs: Insulin receptor family
Type III RTKs: PDGFR, CSFR, Kit, FLT3
receptor family
Type IV RTKs: VEGF (vascular endothelial
growth factor) receptor family
Type V RTKs: FGF (ﬁbroblast growth factor)
receptor family
Type VI RTKs: PTK7/CCK4
Type VII RTKs: Neurotrophin receptor/Trk
family
Type VIII RTKs: ROR family
Type IX RTKs: MuSK
Type X RTKs: HGF (hepatocyte growth
factor) receptor family
Type XI RTKs: TAM (TYRO3-, AXL- and
MER-TK) receptor family
Type XII RTKs: TIE family of angiopoietin
receptors
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S298
S299
S299
S300
S300
S301
S301
S302
–
S302
S303
S304
S304
S305
S306
S308

Type XIII RTKs: Ephrin receptor family
Type XIV RTKs: RET
Type XV RTKs: RYK
Type XVI RTKs: DDR (collagen receptor)
family
Type XVII RTKs: ROS receptors
Type XVIII RTKs: LMR family
Type XIX RTKs: Leukocyte tyrosine kinase
(LTK) receptor family
Type XX RTKs: STYK1
TKL: Tyrosine kinase-like
Receptor serine/threonine kinase (RSTK) family
Type I receptor serine/threonine kinases
Type II receptor serine/threonine kinases
Type III receptor serine/threonine kinases
RSTK functional heteromers
Receptor tyrosine phosphatase (RTP) family
Tumour necrosis factor (TNF) receptor family
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Cytokine receptor family
Catalytic receptors → Cytokine receptor family

Overview: Cytokines are not a clearly deﬁned group of agents,
other than having an impact on immune signalling pathways,
although many cytokines have effects on other systems, such as
in development. A feature of some cytokines, which allows them
to be distinguished from hormones, is that they may be
produced by “non-secretory” cells, for example, endothelial cells.
Within the cytokine receptor family, some subfamilies may be
identiﬁed, which are described elsewhere in the Guide to
PHARMACOLOGY, receptors for the TNF family, the TGF-β
family and the chemokines. Within this group of records are
described Type I cytokine receptors, typiﬁed by interleukin
receptors, and Type II cytokine receptors, exempliﬁed by
interferon receptors. These receptors possess a conserved
extracellular region, known as the cytokine receptor homology
domain (CHD), along with a range of other structural modules,
including extracellular immunoglobulin (Ig)-like and ﬁbronectin

type III (FBNIII)-like domains, a transmembrane domain, and
intracellular homology domains. An unusual feature of this
group of agents is the existence of soluble and decoy receptors.
These bind cytokines without allowing signalling to occur. A
further attribute is the production of endogenous antagonist
molecules, which bind to the receptors selectively and prevent
signalling. A commonality of these families of receptors is the
ligand-induced homo- or hetero-oligomerisation, which results
in the recruitment of intracellular protein partners to evoke
cellular responses, particularly in inﬂammatory or
haematopoietic signalling. Although not an exclusive signalling
pathway, a common feature of the majority of cytokine receptors
is activation of the JAK/STAT pathway. This cascade is based
around the protein tyrosine kinase activity of the Janus kinases
(JAK), which phosphorylate the receptor and thereby facilitate
the recruitment of signal transducers and activators of

transcription (STATs). The activated homo- or heterodimeric
STATs function principally as transcription factors in the nucleus.
Type I cytokine receptors are characterized by two pairs of
conserved cysteines linked via disulﬁde bonds and a C-terminal
WSXWS motif within their CHD. Type I receptors are commonly
classiﬁed into ﬁve groups, based on sequence and structual
homology of the receptor and its cytokine ligand, which is
potentially more reﬂective of evolutionary relationships than an
earlier scheme based on the use of common signal transducing
chains within a receptor complex.
Type II cytokine receptors also have two pairs of conserved
cysteines but with a different arrangement to Type I and also lack
the WSXWS motif.

IL-2 receptor family

Catalytic receptors → Cytokine receptor family → IL-2 receptor family
Overview: The IL-2 receptor family consists of one or more ligand-selective subunits, and a common γ chain (γc): IL2RG, P31785), though IL-4 and IL-7 receptors can form complexes with other
receptor chains. Receptors of this family associate with Jak1 and Jak3, primarily activating Stat5, although certain family members can also activate Stat1, Stat3, or Stat6. Ro264550 has been described as
a selective IL-2 receptor antagonist, which binds to IL-2 [221].
Further reading on IL-2 receptor family
Leonard WJ et al. (2019) The γ_c Family of Cytokines: Basic Biology to Therapeutic Ramiﬁcations.
Immunity 50: 832-850 [PMID:30995502]
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Nomenclature

Interleukin-2 receptor

Interleukin-4 receptor type I

Interleukin-4 receptor type II

Interleukin-7 receptor

Interleukin-9 receptor

Subunits

Interleukin-2 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit β
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)

Interleukin-4 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)

Interleukin-4 receptor subunit α
(Ligand-binding subunit),
Interleukin-13 receptor subunit α1
(Other subunit)

Interleukin-7 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)

Interleukin 9 receptor
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)

Endogenous agonists

IL-2 (IL2, P60568)

IL-4 (IL4, P05112)

IL-13 (IL13, P35225), IL-4 (IL4,
P05112)

IL-7 (IL7, P13232)

IL-9 (IL9, P15248)

Endogenous antagonists

IL-1 receptor antagonist (IL1RN,
P18510)

–

–

–

–

Selective antagonists

AF12198 [1]

–

–

–

–

Nomenclature

Interleukin 13 receptor, α2

Interleukin-15 receptor

Interleukin-21 receptor

Thymic stromal lymphopoietin receptor

HGNC, UniProt

IL13RA2, Q14627

–

–

–

Subunits

–

Interleukin-2 receptor subunit β (Ligand-binding subunit),
Interleukin-15 receptor subunit α (Ligand-binding subunit),
Interleukin-2 receptor subunit γ (Other subunit)

Interleukin 21 receptor (Ligand-binding
Interleukin-7 receptor subunit α
subunit), Interleukin-2 receptor subunit γ (Ligand-binding subunit), Cytokine
(Other subunit)
receptor-like factor 2 (Other subunit)

Endogenous agonists –

IL-15 (IL15, P40933) [265]

IL-21 (IL21, Q9HBE4)

thymic stromal lymphopoietin (TSLP,
Q969D9)

Comments

–

–

–

Decoy receptor that binds IL-13
(IL13, P35225) as a monomer.

Subunits

Nomenclature

Interleukin-2 receptor subunit α

Interleukin-2 receptor subunit β

Interleukin-2 receptor subunit γ

Interleukin-4 receptor subunit α

Interleukin-7 receptor subunit α

HGNC, UniProt

IL2RA, P01589

IL2RB, P14784

IL2RG, P31785

IL4R, P24394

IL7R, P16871

Antibodies

daclizumab (Binding) (pKd >8)
[191], basiliximab (Binding)

–

–

dupilumab (Binding) (pIC50 11.1)
[154]

–

Nomenclature

Interleukin 9 receptor

Interleukin-13 receptor subunit α1

Interleukin-15 receptor subunit α

Interleukin 21 receptor

Cytokine receptor-like factor 2

HGNC, UniProt

IL9R, Q01113

IL13RA1, P78552

IL15RA, Q13261

IL21R, Q9HBE5

CRLF2, Q9HC73

Searchable database: http://www.guidetopharmacology.org/index.jsp
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IL-3 receptor family

Catalytic receptors → Cytokine receptor family → IL-3 receptor family
Overview: The IL-3 receptor family signal through a receptor complex comprising of a ligand-speciﬁc α subunit and a common β chain (CSF2RB, P32927), which is associated with Jak2 and signals
primarily through Stat5.

Nomenclature

Interleukin-3 receptor

Interleukin-5 receptor

Granulocyte macrophage colony-stimulating factor receptor

Subunits

Interleukin 3 receptor, α subunit (Ligand-binding subunit),
Cytokine receptor common β subunit (Other subunit)

Interleukin 5 receptor, α subunit (Ligand-binding subunit),
Cytokine receptor common β subunit (Other subunit)

GM-CSF receptor, α subunit (Ligand-binding subunit),
Cytokine receptor common β subunit (Other subunit)

Endogenous agonists IL-3 (IL3, P08700)

IL-5 (IL5, P05113)

G-CSF (CSF3, P09919), GM-CSF (CSF2, P04141)

Selective antagonists

YM90709 [167]

–

–

Subunits

Nomenclature

Interleukin 3 receptor, α subunit

Interleukin 5 receptor, α subunit

GM-CSF receptor, α subunit

HGNC, UniProt

IL3RA, P26951

IL5RA, Q01344

CSF2RA, P15509

Cytokine receptor common β subunit
CSF2RB, P32927

Endogenous agonists

IL-3 (IL3, P08700)

IL-5 (IL5, P05113)

GM-CSF (CSF2, P04141)

–

Antibodies

–

benralizumab (Binding) (pKd 8.7) [122]

mavrilimumab (Binding) (pIC50 9.9) [35]

–

IL-6 receptor family

Catalytic receptors → Cytokine receptor family → IL-6 receptor family
Overview: The IL-6 receptor family signal through a ternary receptor complex consisting of the cognate receptor and either the IL-6 signal transducer gp130 (IL6ST, P40189) or the oncostatin
M-speciﬁc receptor, β subunit (OSMR, Q99650), which then activates the JAK/STAT, Ras/Raf/MAPK and PI 3-kinase/PKB signalling modules. Unusually amongst the cytokine receptors, the CNTF receptor
is a glycerophosphatidylinositol-linked protein.
Further reading on IL-6 receptor family
Ho LJ et al. (2015) Biological effects of interleukin-6: Clinical applications in autoimmune diseases
and cancers. Biochem Pharmacol 97: 16-26 [PMID:26080005]
Kang S et al. (2019) Targeting Interleukin-6 Signaling in Clinic. Immunity 50: 1007-1023
[PMID:30995492]

Murakami M et al. (2019) Pleiotropy and Speciﬁcity: Insights from the Interleukin 6 Family of
Cytokines. Immunity 50: 812-831 [PMID:30995501]
Rothaug M et al. (2016) The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta
1863: 1218-27 [PMID:27016501]

Searchable database: http://www.guidetopharmacology.org/index.jsp
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.15541/full

IL-6 receptor family S268

S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2021/22: Catalytic receptors. British Journal of Pharmacology (2021) 178, S264-S312

Nomenclature

Interleukin-6 receptor

Interleukin-11
receptor

Subunits

Interleukin-6 receptor, α subunit
(Ligand-binding subunit),
Interleukin-6 receptor, β subunit
(Other subunit)

Interleukin-11
receptor, α subunit
(Ligand-binding
subunit), Interleukin-6
receptor, β subunit
(Other subunit)

Endogenous
agonists

Interleukin-27
receptor

Interleukin-31
receptor

Ciliary neutrophic factor
receptor

Leukemia inhibitory
factor receptor

Oncostatin-M
receptor

Interleukin-6 receptor, Interleukin-31
receptor, α subunit
subunit), Interleukin
(Ligand-binding
27 receptor, alpha
subunit), Oncostatin
(Ligand-binding
M-speciﬁc receptor,
subunit)
β subunit (Other
subunit)

Ciliary neurotrophic factor
receptor α subunit
(Ligand-binding subunit),
Leukemia inhibitory factor
receptor (Other subunit),
Interleukin-6 receptor,
β subunit

Leukemia inhibitory
factor receptor
(Ligand-binding
subunit), Interleukin-6
receptor, β subunit
(Other subunit)

Oncostatin M-speciﬁc
receptor, β subunit
(Ligand-binding
subunit), Interleukin-6
receptor, β subunit
(Other subunit)

IL-6 (IL6, P05231) (Murine NIH/3T3
IL-11 (IL11, P20809)
ﬁbroblasts with human IL6R exhibited
a single class of binding sites for
125I-labeled recombinant human
interleukin-6 (125I-rhIL-6) (Kd = 440
pM, 20,000 receptors per cell).) [194]

IL-27 (EBI3 IL27,
Q14213 Q8NEV9)

IL-31 (IL31, Q6EBC2)

CRCF1/CLCF1 heterodimer
(CLCF1 CRLF1, O75462
Q9UBD9), ciliary
neurotrophic factor (CNTF,
P26441)

LIF (LIF, P15018),
cardiotrophin-1
(CTF1, Q16619),
oncostatin M (OSM,
P13725)

oncostatin M (OSM,
P13725)

Agonists

–

oprelvekin [13, 243]

–

–

–

–

–

Antibodies

vobarilizumab (Binding) (pKd 12.7)
[231], satralizumab (Binding) (pKd
8.9) [103], tocilizumab (Binding)
(pKd 8.6)

–

–

–

–

–

–

β subunit (Other

Subunits

Nomenclature

Interleukin-6 receptor, α subunit

Interleukin-6 receptor, β subunit

Systematic nomenclature

interleukin 6 receptor

interleukin 6 signal transducer

Common abbreviation

IL6R

IL6ST

HGNC, UniProt

IL6R, P08887

IL6ST, P40189

Endogenous agonists

IL-6 (IL6, P05231) (IL6R) expressed stably in murine NIH/3T3 ﬁbroblasts.exhibited a single class of binding sites for 125I-labeled recombinant
human interleukin-6 (125I-rhIL-6) (Kd = 440 pM, 20,000 receptors per cell).) [194]

–

Antibodies

sarilumab (Binding) (pKd 10.6–11.1) [215]

–

Searchable database: http://www.guidetopharmacology.org/index.jsp
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Nomenclature

Interleukin-11 receptor,
α subunit

Interleukin 27 receptor,
alpha

Interleukin-31 receptor,
α subunit

Ciliary neurotrophic
Leptin receptor
factor receptor α subunit

Leukemia inhibitory
factor receptor

Oncostatin M-speciﬁc
receptor, β subunit

HGNC, UniProt

IL11RA, Q14626

IL27RA, Q6UWB1

IL31RA, Q8NI17

CNTFR, P26992

LEPR, P48357

LIFR, P42702

OSMR, Q99650

–

–

–

leptin (LEP, P41159)
[233] – Mouse

–

–

Endogenous agonists –

IL-12 receptor family

Catalytic receptors → Cytokine receptor family → IL-12 receptor family
Overview: IL-12 receptors are a subfamily of the IL-6 receptor family. IL12RB1 is shared between receptors for IL-12 and IL-23; the functional agonist at IL-12 receptors is a heterodimer of
IL-12A/IL-12B, while that for IL-23 receptors is a heterodimer of IL-12B/IL-23A.
Further reading on IL-12 receptor family
Tait Wojno ED et al. (2019) The Immunobiology of the Interleukin-12 Family: Room for
Discovery. Immunity 50: 851-870 [PMID:30995503]

Nomenclature

Interleukin-12 receptor

Interleukin-23 receptor

HGNC, UniProt

–

–

Subunits

Interleukin-12 receptor, β1 subunit (Ligand-binding subunit), Interleukin-12 receptor, β2
subunit (Other subunit)

Interleukin-12 receptor, β1 subunit (Ligand-binding subunit), Interleukin 23 receptor
(Ligand-binding subunit)

Endogenous agonists

IL-12 (IL12A IL12B, P29459 P29460)

IL-23 (IL12B IL23A, P29460)

Subunits

Nomenclature

Interleukin-12 receptor, β1 subunit

Interleukin-12 receptor, β2 subunit

Interleukin 23 receptor

HGNC, UniProt

IL12RB1, P42701

IL12RB2, Q99665

IL23R, Q5VWK5

Searchable database: http://www.guidetopharmacology.org/index.jsp
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Prolactin receptor family

Catalytic receptors → Cytokine receptor family → Prolactin receptor family
Overview: Prolactin family receptors form homodimers in the presence of their respective ligands, associate exclusively with Jak2 and signal via Stat5.
Further reading on Prolactin receptor family
Cabrera-Reyes EA et al. (2017) Prolactin function and putative expression in the brain. Endocrine
57: 199-213 [PMID:28634745]

Gofﬁn V. (2017) Prolactin receptor targeting in breast and prostate cancers: New insights into an
old challenge. Pharmacol Ther 179: 111-126 [PMID:28549597]

Nomenclature

Eythropoietin receptor

Granulocyte colony-stimulating
factor receptor

Growth hormone receptor

Prolactin receptor

Thrombopoietin receptor

HGNC, UniProt

EPOR, P19235

MPL, P40238

CSF3R, Q99062

GHR, P10912

PRLR, P16471

Endogenous agonists erythropoietin (EPO,
P01588) [57]

G-CSF (CSF3, P09919)

growth hormone 1 (GH1,
P01241), growth hormone
2 (GH2, P01242)

prolactin (PRL, P01236) [61] – Mouse, choriomammotropin thrombopoietin (THPO,
(CSH1 CSH2, P01243), chorionic somatomammotropin
P40225)
hormone-like 1 (CSHL1, Q14406)

Agonists

peginesatide [57]

pegﬁlgrastim

–

–

hetrombopag, romiplostim

Selective agonists

–

–

–

–

eltrombopag [151]

Antagonists

–

–

pegvisomant [225]

–

–
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Interferon receptor family

Catalytic receptors → Cytokine receptor family → Interferon receptor family
Overview: The interferon receptor family includes receptors for
type I (α, β κ and ω) and type II (γ) interferons. There are at least
13 different genes encoding IFN-α subunits in a cluster on human

chromosome 9p22: α1 (IFNA1, P01562), α2 (IFNA2, P01563), α4
(IFNA4, P05014), α5 (IFNA5, P01569), α6 (IFNA6, P05013), α7
(IFNA7, P01567), α8 (IFNA8, P32881), α10 (IFNA10, P01566), α13

(IFNA13, P01562), α14 (IFNA14, P01570), α16 (IFNA16, P05015),
α17 (IFNA17, P01571) and α21 (IFNA21, P01568).

Further reading on Interferon receptor family
Kotenko SV et al. (2017) Contribution of type III interferons to antiviral immunity: location,
location, location. J Biol Chem 292: 7295-7303 [PMID:28289095]
Lazear HM et al. (2019) Shared and Distinct Functions of Type I and Type III Interferons. Immunity
50: 907-923 [PMID:30995506]

Ng CT et al. (2016) Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic
Outcomes. Cell 164: 349-52 [PMID:26824652]
Schreiber G. (2017) The molecular basis for differential type I interferon signaling. J Biol Chem
292: 7285-7294 [PMID:28289098]

Nomenclature

Interferon-α/β receptor

Interferon-γ receptor

Subunits

Interferon α/β receptor 2 (Other subunit), interferon α/β receptor 1 (Ligand-binding subunit)

Interferon γ receptor 1 (Ligand-binding
subunit), Interferon γ receptor 2 (Other subunit)

Endogenous agonists IFN-α1/13 (IFNA1 IFNA13, P01562), IFN-α10 (IFNA10, P01566), IFN-α14 (IFNA14, P01570), IFN-α16 (IFNA16, P05015), IFN-α17 (IFNA17, IFN-γ (IFNG, P01579)
P01571), IFN-α2 (IFNA2, P01563), IFN-α21 (IFNA21, P01568), IFN-α4 (IFNA4, P05014), IFN-α5 (IFNA5, P01569), IFN-α6 (IFNA6,
P05013), IFN-α7 (IFNA7, P01567), IFN-α8 (IFNA8, P32881), IFN-β (IFNB1, P01574), IFN-κ (IFNK, Q9P0W0), IFN-ω (IFNW1, P05000)
Selective agonists

peginterferon alfa-2b [238]

–

Subunits

Nomenclature

interferon α/β receptor 1

Interferon α/β receptor 2

Interferon γ receptor 1

HGNC, UniProt

IFNAR1, P17181

IFNAR2, P48551

IFNGR1, P15260

IFNGR2, P38484

Endogenous agonists

IFN-β (IFNB1, P01574) [259]

–

–

–

Selective agonists

peginterferon alfa-2b [238]

–

–

–

Antibodies

anifrolumab (Binding) (pKd >10) [28]

–

–

–
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IL-10 receptor family

Catalytic receptors → Cytokine receptor family → IL-10 receptor family
Overview: The IL-10 family of receptors are heterodimeric combinations of family members: IL10RA/IL10RB responds to IL-10; IL20RA/IL20RB responds to IL-19, IL-20 and IL-24; IL22RA1/IL20RB
responds to IL-20 and IL-24; IL22RA1/IL10RB responds to IL-22; IFNLR1(previouly known as IL28RA)/IL10RB responds to IFN-λ1, -λ2 and -λ3 (previouly known as IL-29, IL-28A and IL-28B respectively).
Further reading on IL-10 receptor family
Felix J et al. (2017) Mechanisms of immunomodulation by mammalian and viral decoy receptors:
insights from structures. Nat Rev Immunol 17: 112-129 [PMID:28028310]

Ouyang W et al. (2019) IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical
Translation. Immunity 50: 871-891 [PMID:30995504]

Nomenclature

Interleukin-10 receptor

Interleukin-20 receptor

Interleukin-22α1/20β
heteromer

Interleukin-22α1/10β
heteromer

Interleukin-22 receptor α2

Interferon-λ receptor 1

HGNC, UniProt

–

–

–

–

IL22RA2, Q969J5

–

Subunits

Interleukin 10 receptor,
Interleukin 20 receptor, α subunit
α subunit (Ligand-binding (Ligand-binding subunit), Interleukin
subunit), Interleukin 10
20 receptor, β subunit (Other subunit)
receptor, β subunit (Other

Interleukin 10 receptor,

–

Interleukin 10 receptor,
β subunit (Other subunit),
Interferon-λ receptor
subunit 1 (Ligand-binding
subunit)

subunit)

Interleukin 20 receptor,
β subunit (Ligand-binding
subunit), Interleukin 22
receptor, α1 subunit
(Ligand-binding subunit)

β subunit (Ligand-binding
subunit), Interleukin 22
receptor, α1 subunit
(Ligand-binding subunit)

Endogenous
agonists

IL-10 (IL10, P22301)

IL-19 (IL19, Q9UHD0), IL-20 (IL20,
Q9NYY1), IL-24 (IL24, Q13007)

IL-20 (IL20, Q9NYY1),
IL-24 (IL24, Q13007)

IL-22 (IL22, Q9GZX6)

–

IFN-λ1 (IFNL1, Q8IU54),
IFN-λ2 (IFNL2, Q8IZJ0),
IFN-λ3 (IFNL3, Q8IZI9)

Comments

–

–

–

–

Soluble decoy receptor that binds
IL-22 (IL22, Q9GZX6) as a monomer.

–

Subunits

Nomenclature

Interleukin 10 receptor,
α subunit

Interleukin 10 receptor,
β subunit

Interleukin 20 receptor,
α subunit

Interleukin 20 receptor,
β subunit

Interleukin 22 receptor, α1
subunit

Interferon-λ receptor
subunit 1

HGNC, UniProt

IL10RA, Q13651

IL10RB, Q08334

IL20RA, Q9UHF4

IL20RB, Q6UXL0

IL22RA1, Q8N6P7

IFNLR1, Q8IU57
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Immunoglobulin-like family of IL-1 receptors
Catalytic receptors → Cytokine receptor family → Immunoglobulin-like family of IL-1 receptors

Overview: The immunoglobulin-like family of IL-1 receptors are heterodimeric receptors made up of a cognate receptor subunit and an IL-1 receptor accessory protein, IL1RAP (Q9NPH3, also known as
C3orf13, IL-1RAcP, IL1R3). They are characterised by extracellular immunoglobulin-like domains and an intracellular Toll/Interleukin-1R (TIR) domain.
Further reading on Immunoglobulin-like family of IL-1 receptors
Afonina IS et al. (2015) Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a
Common Theme. Immunity 42: 991-1004 [PMID:26084020]

Mantovani A et al. (2019) Interleukin-1 and Related Cytokines in the Regulation of Inﬂammation
and Immunity. Immunity 50: 778-795 [PMID:30995499]

Nomenclature

Interleukin-1 receptor, type I

Interleukin-33 receptor

Interleukin-36 receptor

Interleukin-1 receptor, type II

Interleukin-18 receptor

Subunits

Interleukin 1 receptor, type I
(Ligand-binding subunit), IL-1
receptor accessory protein (Other
subunit)

Interleukin-1 receptor-like 1
(Ligand-binding subunit), IL-1
receptor accessory protein (Other
subunit)

Interleukin-1 receptor-like 2
(Ligand-binding subunit), IL-1
receptor accessory protein (Other
subunit)

IL-1 receptor accessory protein
(Other subunit), Interleukin 1
receptor, type II (Ligand-binding
subunit)

Interleukin-18 receptor 1
(Ligand-binding subunit), IL-18
receptor accessory protein (Other
subunit)

Inhibitors

anakinra (pKd 7.8) [51]

–

–

–

–

Endogenous agonists

IL-1α (IL1A, P01583), IL-1β (IL1B,
P01584)

IL-33 (IL33, O95760)

IL-36α (IL36A, Q9UHA7), IL-36β
(IL36B, Q9NZH7), IL-36γ (IL36G,
Q9NZH8)

–

IL-18 (IL18, Q14116), IL-37 (IL37,
Q9NZH6)

Endogenous antagonists

IL-1 receptor antagonist (IL1RN,
P18510)

–

IL-36 receptor antagonist (IL36RN,
Q9UBH0)

–

–

Selective antagonists

AF12198 [1]

–

–

–

–

Comments

–

–

IL-36 receptor antagonist (IL36RN,
Q9UBH0) is a highly speciﬁc
antagonist of the response to
IL-36γ (IL36G, Q9NZH8).

Decoy receptor that binds IL-1α
(IL1A, P01583), IL-1β (IL1B,
P01584) and IL-1 receptor
antagonist (IL1RN, P18510).

–

Subunits

Nomenclature

Interleukin 1 receptor, type I

Interleukin 1 receptor, type II

Interleukin-1 receptor-like 1

Interleukin-1 receptor-like 2

Interleukin-18 receptor 1

HGNC, UniProt

IL1R1, P14778

IL1R2, P27930

IL1RL1, Q01638

IL1RL2, Q9HB29

IL18R1, Q13478
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IL-17 receptor family

Catalytic receptors → Cytokine receptor family → IL-17 receptor family
Overview: The IL17 cytokine family consists of six ligands (IL-17A-F), which signal through ﬁve receptors (IL-17RA-E).
Further reading on IL-17 receptor family
Beringer A et al. (2016) IL-17 in Chronic Inﬂammation: From Discovery to Targeting. Trends Mol
Med 22: 230-241 [PMID:26837266]
Lubberts E. (2015) The IL-23-IL-17 axis in inﬂammatory arthritis. Nat Rev Rheumatol 11: 415-29
[PMID:25907700]

McGeachy MJ et al. (2019) The IL-17 Family of Cytokines in Health and Disease. Immunity 50:
892-906 [PMID:30995505]

Nomenclature

Interleukin-17 receptor

Interleukin-25 receptor

Interleukin-17C receptor

Subunits

Interleukin 17 receptor A (Ligand-binding subunit),
interleukin 17 receptor C (Other subunit)

Interleukin 17 receptor A (Other subunit), Interleukin 17
receptor B (Ligand-binding subunit)

Interleukin 17 receptor A (Other subunit), Interleukin 17
receptor E (Ligand-binding subunit)

Endogenous agonists

IL-17A (IL17A, Q16552), IL-17A/IL-17F (IL17A IL17F,
Q16552 Q96PD4), IL-17F (IL17F, Q96PD4)

IL-17B (IL17B, Q9UHF5), IL-25 (IL25, Q9H293)

IL-17C (IL17C, Q9P0M4)

Subunits

Nomenclature

Interleukin 17 receptor A

Interleukin 17 receptor B

interleukin 17 receptor C

Interleukin-17 receptor D

Interleukin 17 receptor E

HGNC, UniProt

IL17RA, Q96F46

IL17RB, Q9NRM6

IL17RC, Q8NAC3

IL17RD, Q8NFM7

IL17RE, Q8NFR9

Antibodies

brodalumab (Binding) (pKd 9.2) [224]

–

–

–

–

Comments

–

–

–

The endogenous agonist for this receptor is unknown.

–
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GDNF receptor family
Catalytic receptors → GDNF receptor family

Overview: GDNF family receptors (provisional nomenclature) are extrinsic tyrosine kinase receptors. Ligand binding to the extracellular domain of the glycosylphosphatidylinositol-linked cell-surface
receptors (tabulated below) activates a transmembrane tyrosine kinase enzyme, RET (see Receptor Tyrosine Kinases). The endogenous ligands are typically dimeric, linked through disulphide bridges:
glial cell-derived neurotrophic factor GDNF (GDNF, P39905) (211 aa); neurturin (NRTN, Q99748) (197 aa); artemin (ARTN, Q5T4W7) (237 aa) and persephin (PSPN, O60542) (PSPN, 156 aa).
Further reading on GDNF receptor family
Allen SJ et al. (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration.
Pharmacol Ther 138: 155-75 [PMID:23348013]
Ibáñez CF et al. (2017) Biology of GDNF and its receptors - Relevance for disorders of the central
nervous system. Neurobiol Dis 97: 80-89 [PMID:26829643]

Merighi A. (2016) Targeting the glial-derived neurotrophic factor and related molecules for
controlling normal and pathologic pain. Expert Opin Ther Targets 20: 193-208
[PMID:26863504]

Nomenclature

GDNF family receptor α1

GDNF family receptor α2

GDNF family receptor α3

GDNF family receptor α4

Common abbreviation

GFRα1

GFRα2

GFRα3

GFRα4

HGNC, UniProt

GFRA1, P56159

GFRA2, O00451

GFRA3, O60609

GFRA4, Q9GZZ7

Potency order

GDNF (GDNF, P39905) > neurturin (NRTN, Q99748) >
artemin (ARTN, Q5T4W7)

neurturin (NRTN, Q99748) > GDNF (GDNF, P39905)

artemin (ARTN, Q5T4W7)

persephin (PSPN, O60542)

Labelled ligands

[125 I]GDNF (rat) (pKd 10.2–11.5) [120, 226]

–

–

–

Comments: Inhibitors of other receptor tyrosine kinases, such as semaxanib, which inhibits VEGF receptor function, may also inhibit Ret function [165]. Mutations of RET and GDNF genes may be
involved in Hirschsprung’s disease, which is characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction.
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Integrins

Catalytic receptors → Integrins
Overview: Integrins are unusual signalling proteins that
function to signal both from the extracellular environment into
the cell, but also from the cytoplasm to the external of the cell.
The intracellular signalling cascades associated with integrin
activation focus on protein kinase activities, such as focal
adhesion kinase and Src. Based on this association between
extracellular signals and intracellular protein kinase activity, we
have chosen to include integrins in the ’Catalytic receptors’
section of the database until more stringent criteria from
NC-IUPHAR allows precise deﬁnition of their classiﬁcation.
Integrins are heterodimeric entities, composed of α and β

subunits, each 1TM proteins, which bind components of the
extracellular matrix or counter-receptors expressed on other
cells. One class of integrin contains an inserted domain (I) in its
α subunit, and if present (in α1, α2, α10, α11, αD, αE, αL, αM and
αX), this I domain contains the ligand binding site. All β
subunits possess a similar I-like domain, which has the capacity
to bind ligand, often recognising the RGD motif. The presence of
an α subunit I domain precludes ligand binding through the β
subunit. Integrins provide a link between ligand and the actin
cytoskeleton (through typically short intracellular domains).
Integrins bind several divalent cations, including a Mg2+ ion in
the I or I-like domain that is essential for ligand binding. Other

cation binding sites may regulate integrin activity or stabilise the
3D structure. Integrins regulate the activity of particular protein
kinases, including focal adhesion kinase and integrin-linked
kinase. Cellular activation regulates integrin ligand afﬁnity via
inside-out signalling and ligand binding to integrins can regulate
cellular activity via outside-in signalling.
Several drugs that target integrins are in clinical use including:
(1) abciximab (αIIbβ3) for short term prevention of coronary
thrombosis, (2) vedolizumab (α4β7) to reduce gastrointestinal
inﬂammation, and (3) natalizumab (α4β1) in some cases of
severe multiple sclerosis.

Further reading on Integrins
Clemetson KJ. (2017) The origins of major platelet receptor nomenclature. Platelets 28: 40-42
[PMID:27715379]
Emsley J et al. (2000) Structural basis of collagen recognition by integrin alpha2beta1. Cell 101:
47-56 [PMID:10778855]
Hamidi H et al. (2016) The complexity of integrins in cancer and new scopes for therapeutic
targeting. Br J Cancer 115: 1017-1023 [PMID:27685444]
Horton ER et al. (2016) The integrin adhesome network at a glance. J Cell Sci 129: 4159-4163
[PMID:27799358]

Ley K et al. (2016) Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev
Drug Discov 15: 173-83 [PMID:26822833]
Manninen A et al. (2017) A proteomics view on integrin-mediated adhesions. Proteomics 17:
[PMID:27723259]
Raab-Westphal S et al. (2017) Integrins as Therapeutic Targets: Successes and Cancers. Cancers
(Basel) 9: [PMID:28832494]

Nomenclature

integrin α1β1

integrin α2β1

integrin αIIbβ3

integrin α4β1

Subunits

integrin, alpha 1 subunit, integrin,
beta 1 subunit (ﬁbronectin receptor,
beta polypeptide, antigen CD29
includes MDF2, MSK12)

integrin, alpha 2 subunit (CD49B, alpha 2 subunit
of VLA-2 receptor), integrin, beta 1 subunit
(ﬁbronectin receptor, beta polypeptide, antigen
CD29 includes MDF2, MSK12)

integrin, alpha IIb subunit (platelet
glycoprotein IIb of IIb/IIIa complex, antigen
CD41), integrin, beta 3 subunit (platelet
glycoprotein IIIa, antigen CD61)

integrin, alpha 4 subunit (antigen CD49D, alpha 4
subunit of VLA-4 receptor), integrin, beta 1 subunit
(ﬁbronectin receptor, beta polypeptide, antigen
CD29 includes MDF2, MSK12)

Ligands

collagen, laminin

collagen, laminin, thrombospondin

ﬁbrinogen (FGA FGB FGG, P02671 P02675
P02679), ﬁbronectin (FN1, P02751), von
Willebrand factor (VWF, P04275), vitronectin
(VTN, P04004), thrombospondin

ﬁbronectin (FN1, P02751), vascular cell adhesion
protein 1 (VCAM1, P19320), osteopontin (SPP1,
P10451), thrombospondin

Inhibitors

obtustatin (pIC50 9.1) [150]

TCI15 (pIC50 7.9) [162], BTT-3033 [174]

tiroﬁban (pIC50 9.4) [227], G4120 (pKi 8.4)
[157, 254], GR 144053 (pIC50 7.4) [53],
eptiﬁbatide (pIC50 6.2–6.8) [199]

BIO1211 (pIC50 8.3–9) [137], carotegrast (pIC50
7.2) [147], TCS2314, ﬁrategrast [79], valategrast
[95], zaurategrast [247]

Antibodies

–

–

abciximab (Binding) [37]

natalizumab (Inhibition) [175]

Comments

–

–

–

LDV-FITC is used as a probe at this receptor.
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Nomenclature

integrin α4β7

integrin α5β1

integrin α6β1

integrin α10β1

Subunits

integrin, alpha 4 subunit (antigen CD49D, alpha 4
subunit of VLA-4 receptor), integrin, beta 7 subunit

integrin, alpha 5 subunit (ﬁbronectin receptor,
alpha polypeptide), integrin, beta 1 subunit
(ﬁbronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12)

integrin, alpha 6 subunit, integrin, beta 1
subunit (ﬁbronectin receptor, beta
polypeptide, antigen CD29 includes
MDF2, MSK12)

integrin, alpha 10 subunit, integrin, beta 1
subunit (ﬁbronectin receptor, beta
polypeptide, antigen CD29 includes
MDF2, MSK12)

Ligands

–

ﬁbronectin (FN1, P02751)

laminin

collagen

Inhibitors

ﬁrategrast [79], valategrast [95], zaurategrast [247]

–

–

–

Antibodies

vedolizumab (Antagonist) (pIC50 8.3) [189]

volociximab (Binding) (pKd 9.5) [14, 15]

–

–

Nomenclature

integrin α11β1

integrin αEβ7

integrin αLβ2

integrin αVβ3

Subunits

integrin, alpha 11 subunit, integrin,
beta 1 subunit (ﬁbronectin receptor,
beta polypeptide, antigen CD29
includes MDF2, MSK12)

integrin, alpha E subunit (antigen
CD103, human mucosal lymphocyte
antigen 1; alpha polypeptide),
integrin, beta 7 subunit

integrin, alpha L subunit (antigen CD11A (p180),
lymphocyte function-associated antigen 1; alpha
polypeptide), integrin, beta 2 subunit (complement
component 3 receptor 3 and 4 subunit)

integrin, alpha V subunit, integrin, beta 3 subunit
(platelet glycoprotein IIIa, antigen CD61)

Ligands

collagen

E-cadherin

ICAM-1 (ICAM1, P05362), ICAM-2 (ICAM2, P13598)

vitronectin (VTN, P04004), ﬁbronectin (FN1, P02751),
ﬁbrinogen (FGA FGB FGG, P02671 P02675 P02679),
osteopontin (SPP1, P10451), von Willebrand factor
(VWF, P04275), thrombospondin, tenascin

Activators

–

–

–

TP508 (pKd 7.9) [48]

Inhibitors

–

–

A286982 (pIC50 7.4–7.5) [140]

–

Antagonists

–

–

–

echistatin (pIC50 11.7) [131], P11 (pIC50 11.6) [131],
CWHM12 (pIC50 9.1) [94], cilengitide (pIC50 8.5)
[76], GSK2603566A (pIC50 8.4) [4]

Antibodies

–

etrolizumab (Inhibition) [214]

–

etaracizumab (Binding) (pKd 6.3) [249]
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Subunits

Nomenclature

integrin, alpha 1
subunit

integrin, alpha 2 subunit (CD49B, integrin, alpha IIb subunit
alpha 2 subunit of VLA-2
(platelet glycoprotein IIb of
receptor)
IIb/IIIa complex, antigen CD41)

integrin, alpha 3 subunit (antigen integrin, alpha 4 subunit (antigen integrin, alpha 5 subunit
CD49C, alpha 3 subunit of
CD49D, alpha 4 subunit of VLA-4 (ﬁbronectin receptor,
VLA-3 receptor)
receptor)
alpha polypeptide)

HGNC, UniProt

ITGA1, P56199

ITGA2, P17301

ITGA2B, P08514

ITGA3, P26006

Ligands

–

–

–

peptide ligand 2 (Binding) (pIC50 –
7.2) [253]

–

Antibodies

–

–

–

–

volociximab (Binding)
(pKd 9.5) [14, 15]

Nomenclature

integrin, alpha 6 subunit

integrin, alpha 7 subunit

integrin, alpha 8 subunit

integrin, alpha 9 subunit

integrin, alpha 10 subunit integrin, alpha 11 subunit integrin, alpha D subunit

HGNC, UniProt

ITGA6, P23229

ITGA7, Q13683

ITGA8, P53708

ITGA9, Q13797

ITGA10, O75578

Nomenclature

integrin, alpha E subunit
(antigen CD103, human
mucosal lymphocyte antigen 1;
alpha polypeptide)

integrin, alpha L subunit (antigen
CD11A (p180), lymphocyte
function-associated antigen 1; alpha
polypeptide)

integrin, alpha M subunit
(complement component
3 receptor 3 subunit)

HGNC, UniProt

ITGAE, P38570

ITGAL, P20701

Antagonists

–

liﬁtegrast (Inhibition) [20, 261]

Antibodies

–

efalizumab (Binding) (pKd 11.4) [107]

ITGA4, P13612

ITGA5, P08648

natalizumab (Inhibition) [175]

ITGA11, Q9UKX5

ITGAD, Q13349

integrin, alpha V subunit

integrin, alpha X subunit
(complement component
3 receptor 4 subunit)

integrin, beta 1 subunit
(ﬁbronectin receptor, beta
polypeptide, antigen CD29
includes MDF2, MSK12)

ITGAM, P11215

ITGAV, P06756

ITGAX, P20702

ITGB1, P05556

–

MK-0429 (pIC50 7.1) [101] –

–

–

–

–
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Nomenclature

integrin, beta 2 subunit
(complement component
3 receptor 3 and 4 subunit)

integrin, beta 3 subunit
(platelet glycoprotein IIIa,
antigen CD61)

integrin, beta 4
subunit

integrin, beta 5 subunit

integrin, beta 6 subunit

integrin, beta 7
subunit

integrin, beta 8 subunit

HGNC, UniProt

ITGB2, P05107

ITGB3, P05106

ITGB4, P16144

ITGB5, P18084

ITGB6, P18564

ITGB7, P26010

ITGB8, P26012

Inhibitors

–

Selective inhibitors –

compound 7 (pKi 6.8) [10]

–

compound 7 (pKi 7.3) [10]

–

–

compound 7 (pKi 7.6) [10]

–

–

–

compound 7 (pKi 10) [10]

–

–

Comments: Integrin ligands
Collagen is the most abundant protein in metazoa, rich in
glycine and proline residues, made up of cross-linked triple
helical structures, generated primarily by ﬁbroblasts. Extensive
post-translational processing is conducted by prolyl and lysyl
hydroxylases, as well as transglutaminases. Over 40 genes for
collagen-α subunits have been identiﬁed in the human genome.
The collagen-binding integrins α1β1, α2β1, α10β1 and α11β1
recognise a range of triple-helical peptide motifs including
GFOGER (O = hydroxyproline), a synthetic peptide derived from
the primary sequence of collagen I (COL1A1 (COL1A1,
P02452)) and collagen II (COL2A1 (COL2A1, P02458)).
Laminin is an extracellular glycoprotein composed of α, β and γ
chains, for which ﬁve, four and three genes, respectively, are
identiﬁed in the human genome. It binds to α1β1, α2β1, α3,β1,
α7β1 and α6β4 integrins10.

ﬁbrinogen (FGA FGB FGG, P02671 P02675 P02679) is a
glycosylated hexamer composed of two α (FGA, P02671), two β
(FGB, P02675) and two γ (FGG, P02679,) subunits, linked by
disulphide bridges. It is found in plasma and alpha granules of
platelets. It forms cross-links between activated platelets
mediating aggregation by binding αIIbβ3; proteolysis by
thrombin cleaves short peptides termed ﬁbrinopeptides to
generate ﬁbrin, which polymerises as part of the blood
coagulation cascade.

osteopontin (SPP1, P10451) forms an integral part of the
mineralized matrix in bone, where it undergoes extensive
post-translation processing, including proteolysis and
phosphorylation.

ﬁbronectin (FN1, P02751) is a disulphide-linked homodimer
found as two major forms; a soluble dimeric form found in the
plasma and a tissue version that is polymeric, which is secreted
into the extracellular matrix by ﬁbroblasts. Splice variation of
the gene product (FN1, P02751) generates multiple
isoforms.

von Willebrand factor (VWF, P04275) is a glycoprotein
synthesised in vascular endothelial cells as a disulphide-linked
homodimer, but multimerises further in plasma and is deposited
on vessel wall collagen as a high molecular weight multimer. It is
responsible for capturing platelets under arterial shear ﬂow (via
GPIb) and in thrombus propagation (via integrin
αIIbβ3).

Searchable database: http://www.guidetopharmacology.org/index.jsp
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vitronectin (VTN, P04004) is a serum glycoprotein and
extracellular matrix protein which is found either as a monomer
or, following proteolysis, a disulphide -linked
dimer.
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Pattern recognition receptors
Catalytic receptors → Pattern recognition receptors

Overview: Pattern Recognition Receptors (PRRs, [218])
(nomenclature as agreed by NC-IUPHAR sub-committee
on Pattern Recognition Receptors, [24]) participate in the
innate immune response to microbial agents, the stimulation of
which leads to activation of intracellular enzymes and regulation
of gene transcription. PRRs express multiple leucine-rich regions
to bind a range of microbially-derived ligands, termed PAMPs or
pathogen-associated molecular patterns or endogenous ligands,
termed DAMPS or damage-associated molecular patterns. These
include peptides, carbohydrates, peptidoglycans, lipoproteins,
lipopolysaccharides, and nucleic acids. PRRs include both
cell-surface and intracellular proteins. PRRs may be divided into

signalling-associated members, identiﬁed here, and endocytic
members, the function of which appears to be to recognise
particular microbial motifs for subsequent cell attachment,
internalisation and destruction. Some are involved in
inﬂammasome formation, and modulation of IL-1β cleavage and
secretion, and others in the initiation of the type I interferon
response.

Nucleotide-binding oligomerization domain, leucine-rich repeat
containing receptors (NLRs, also known as NOD (Nucleotide
oligomerisation domain)-like receptors)

PRRs included in the Guide To PHARMACOLOGY are:

Absent in melanoma (AIM)-like receptors (ALRs)

RIG-I-like receptors (RLRs)
Caspase 4 and caspase 5
Non-catalytic PRRs
C-type lectin-like receptors (CLRs)

Catalytic PRRs (see links below this overview)

Other pattern recognition receptors

Toll-like receptors (TLRs)

Advanced glycosylation end-product speciﬁc receptor (RAGE)

Further reading on Pattern recognition receptors
Broz P et al. (2016) Inﬂammasomes: mechanism of assembly, regulation and signalling. Nat Rev
Immunol 16: 407-20 [PMID:27291964]
Bryant CE et al. (2015) Advances in Toll-like receptor biology: Modes of activation by diverse
stimuli. Crit Rev Biochem Mol Biol 50: 359-79 [PMID:25857820]
Feerick CL et al. (2017) Understanding the regulation of pattern recognition receptors in
inﬂammatory diseases - a ’Nod’ in the right direction. Immunology 150: 237-247
[PMID:27706808]

Rathinam VA et al. (2016) Inﬂammasome Complexes: Emerging Mechanisms and Effector
Functions. Cell 165: 792-800 [PMID:27153493]
Unterholzner L. (2013) The interferon response to intracellular DNA: why so many receptors?
Immunobiology 218: 1312-21 [PMID:23962476]
Yin Q et al. (2015) Structural biology of innate immunity. Annu Rev Immunol 33: 393-416
[PMID:25622194]

Toll-like receptor family

Catalytic receptors → Pattern recognition receptors → Toll-like receptor family
Overview: Members of the toll-like family of receptors
(nomenclature recommended by the NC-IUPHAR subcommittee
on pattern recognition receptors, [24]) share signiﬁcant
homology with the interleukin-1 receptor family and appear to
require dimerization either as homo- or heterodimers for

functional activity. Heterodimerization appears to inﬂuence the
potency of ligand binding substantially (e.g. TLR1/2 and TLR2/6,
[219, 220]). TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are
cell-surface proteins, while other members are associated with
intracellular organelles, signalling through the

Searchable database: http://www.guidetopharmacology.org/index.jsp
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MyD88-dependent pathways (with the exception of TLR3). As
well as responding to exogenous infectious agents [59], it has
been suggested that selected members of the family may be
activated by endogenous ligands, such as hsp60 (HSPD1, P10809)
[176].
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Further reading on Toll-like receptor family
Anthoney N et al. (2018) Toll and Toll-like receptor signalling in development. Development 145:
[PMID:29695493]
Bryant CE et al. (2015) International Union of Basic and Clinical Pharmacology. XCVI. Pattern
recognition receptors in health and disease. Pharmacol Rev 67: 462-504 [PMID:25829385]
Franz KM et al. (2017) Innate Immune Receptors as Competitive Determinants of Cell Fate. Mol
Cell 66: 750-760 [PMID:28622520]

Joosten LA et al. (2016) Toll-like receptors and chronic inﬂammation in rheumatic diseases: new
developments. Nat Rev Rheumatol 12: 344-57 [PMID:27170508]
Nunes KP et al. (2019) Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the
toll for hypertension? Br J Pharmacol 176: 1864-1879 [PMID:29981161]
Zhang Z et al. (2017) Toward a structural understanding of nucleic acid-sensing Toll-like receptors
in the innate immune system. FEBS Lett 591: 3167-3181 [PMID:28686285]

Nomenclature

TLR1

TLR2

TLR3

TLR4

TLR5

HGNC, UniProt

TLR1, Q15399

TLR2, O60603

TLR3, O15455

TLR4, O00206

TLR5, O60602

Agonists

–

compound 13 [102], peptidoglycan [202, 256]

poly(I:C) [3]

LPS [188], paclitaxel [114] – Mouse

ﬂagellin [88]

Selective antagonists

–

–

–

resatorvid [104]

–

Comments

Functions as a heterodimer with TLR2
in detection of triacylated
lipoproteins. Activated by the
synthetic analogue Pam3CSK4.

Functions as a heterodimer with either TLR1 or TLR6 in the
detection of triacylated and diacylated lipopeptides
respectively. TLR1/2 and 2/6 heterodimers can be activated
by the synthetic lipopeptides Pam3CSK4 and Pam2CSK4
respectively. There is some debate in the ﬁeld as to whether
or not peptidoglycan is a direct agonist of TLR2, or whether
the early studies reporting this contained contaminating
lipoproteins.

Involved in
endosomal detection
of dsRNA;
pro-inﬂammatory.

Eritoran (E5564) is a lipid A analogue,
which has been described as a TLR4
antagonist [106]. TLR4 signals in
conjunction with the co-factor MD-2
(LY96).

Involved in the
detection of bacterial
ﬂagellin;
pro-inﬂammatory.

Nomenclature

TLR6

TLR7

TLR8

TLR9

TLR10

TLR11

HGNC, UniProt

TLR6, Q9Y2C9

TLR7, Q9NYK1

TLR8, Q9NR97

TLR9, Q9NR96

TLR10, Q9BXR5

–

Agonists

–

resiquimod [92, 111, 128], imiquimod
[128], loxoribine [90]

resiquimod [92, 111,
128]

–

–

–

Antagonists

–

hydroxychloroquine (pIC50 5.6) [127]

–

hydroxychloroquine (pIC50 7.1) [127]

–

–

Comments

Functions as a
heterodimer with
TLR2. Involved in the
pro-inﬂammatory
response to
diacylated bacterial
lipopeptides.

Activated by imidazoquinoline
derivatives and RNA
oligoribonucleotides. Involved in
endosomal detection of ssRNA;
pro-inﬂammatory.

Activated by
imidazoquinoline
derivatives and RNA
oligoribonucleotides.
Endosomal detection
of ssRNA;
pro-inﬂammatory.

Toll-like receptor 9 interacts with
unmethylated CpG dinucleotides from
bacterial DNA [93]. Activated by CpG
rich DNA sequences;
pro-inﬂammatory.

TLR10 is the only pattern-recognition receptor
without known ligand speciﬁcity and
biological function. Evidence suggests it plays
a modulatory role with predominantly
inhibitory (anti-inﬂammatory) actions [182].
Murine TLR10 has a retroviral insertion that
makes it non-functional.

Found in
mouse
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NOD-like receptor family

Catalytic receptors → Pattern recognition receptors → NOD-like receptor family
Overview: The nucleotide-binding oligomerization domain,
leucine-rich repeat (NLR) family of receptors (nomenclature
recommended by the NC-IUPHAR subcommittee on pattern
recognition receptors [24]) share a common domain
organisation. This consists of an N-terminal effector domain, a
central nucleotide-binding and oligomerization domain (NOD;
also referred to as a NACHT domain), and C-terminal
leucine-rich repeats (LRR) which have regulatory and ligand
recognition functions. The type of effector domain has resulted
in the division of NLR family members into two major

sub-families, NLRC and NLRP, along with three smaller
sub-families NLRA, NLRB and NLRX [222]. NLRC members
express an N-terminal caspase recruitment domain (CARD) and
NLRP members an N-terminal Pyrin domain (PYD).
Upon activation the NLRC family members NOD1 (NLRC1) and
NOD2 (NLRC2) recruit a serine/threonine kinase RIPK2 (receptor
interacting serine/threonine kinase 2, O43353, also known as
CARD3, CARDIAK, RICK, RIP2) leading to signalling through
NFκB and MAP kinase. Activation of NLRC4 (previously known

as IPAF) and members of the NLRP3 family, including NLRP1 and
NLRP3, leads to formation of a large multiprotein complex
known as the inﬂammasome. In addition to NLR proteins other
key members of the inﬂammasome include the adaptor protein
ASC (apoptosis-associated speck-like protein containing a CARD,
also known as PYCARD, CARD5, TMS1, Q9ULZ3) and
inﬂammatory caspases. The inﬂammasome activates the
pro-inﬂammatory cytokines IL-1β (IL1B, P01584) and IL-18
(IL18, Q14116) [24, 43].

Further reading on NOD-like receptor family
Man SM. (2018) Inﬂammasomes in the gastrointestinal tract: infection, cancer and gut microbiota
homeostasis. Nat Rev Gastroenterol Hepatol 15: 721-737 [PMID:30185915]

Broz P et al. (2016) Inﬂammasomes: mechanism of assembly, regulation and signalling. Nat Rev
Immunol 16: 407-20 [PMID:27291964]
Bryant CE et al. (2015) International Union of Basic and Clinical Pharmacology. XCVI. Pattern
recognition receptors in health and disease. Pharmacol Rev 67: 462-504 [PMID:25829385]
Keestra-Gounder AM et al. (2017) NOD1 and NOD2: Beyond Peptidoglycan Sensing. Trends
Immunol 38: 758-767 [PMID:28823510]
Lei-Leston AC et al. (2017) Epithelial Cell Inﬂammasomes in Intestinal Immunity and
Inﬂammation. Front Immunol 8: 1168 [PMID:28979266]

Mukherjee T et al. (2019) NOD1 and NOD2 in inﬂammation, immunity and disease. Arch Biochem
Biophys 670: 69-81 [PMID:30578751]
Nielsen AE et al. (2017) Synthetic agonists of NOD-like, RIG-I-like, and C-type lectin receptors for
probing the inﬂammatory immune response. Future Med Chem 9: 1345-1360 [PMID:28776416]

Nomenclature

nucleotide binding
nucleotide binding
oligomerization
oligomerization domain
domain containing 1 containing 2

NLRC3

NLRC4

NLRC5

NLRX1

CIITA

Common abbreviation

NOD1

NOD2

–

–

–

–

–

HGNC, UniProt

NOD1, Q9Y239

NOD2, Q9HC29

NLRC3, Q7RTR2

NLRC4, Q9NPP4

NLRC5, Q86WI3

NLRX1, Q86UT6

CIITA, P33076

Agonists

meso-DAP

muramyl dipeptide

–

–

–

–

–

Comments

–

NOD2 has also been reported –
to be activated by ssRNA
[196] although this has not
been widely reproduced.

NLRC4 forms an inﬂammasome with the
NAIP proteins following recognition of
bacterial ﬂagellin and type III secretion
system rod proteins by the NAIPs.

–

–

–
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Nomenclature

NLRP1

NLRP2

NLRP3

NLRP4

NLRP5

NLRP6

NLRP7

HGNC, UniProt

NLRP1, Q9C000

NLRP2, Q9NX02

NLRP3, Q96P20

NLRP4, Q96MN2

NLRP5, P59047

NLRP6, P59044

NLRP7, Q8WX94

Inhibitors

–

–

MCC950 (pIC50 >8) [36]

–

–

–

–

Agonists

muramyl dipeptide

–

–

–

–

–

–

Comments

NLRP1 has 3 murine
orthologues which lack
the N-terminal Pyrin
domain. Murine NLRP1b
(ENSMUSG00000070390)
is the best characterised,
responding to Anthrax
Lethal Toxin.

Along with
NLRP7, NLRP2 is
the product of a
primate-speciﬁc
gene duplication.

NLRP3 has been shown to be activated following disruption Expanded in the
of cellular haemostasis by a wide-variety of exogenous and mouse resulting
endogenous molecules. The identity of the precise agonist in 7 orthologues.
that interacts with NLRP3 remains enigmatic. Efﬂux of
potassium ions appears to be a common event for NLRP3
activating molecules. In addition to MCC950 [36] other
small molecules including CY-09 [109], β-hydroxybutyrate
[257], and various boron containing compounds [9]
modulate NLRP3.

–

–

Absent in mouse.
Along with
NLRP2 the
product of a
primate-speciﬁc
gene duplication.

Nomenclature

NLRP8

NLRP9

NLRP10

NLRP11

NLRP12

NLRP13

NLRP14

HGNC, UniProt

NLRP8, Q86W28

NLRP9, Q7RTR0

NLRP10, Q86W26

NLRP11, P59045

NLRP12, P59046

NLRP13, Q86W25

NLRP14, Q86W24

Comments

Absent in mouse

This receptor has three
murine orthologues.

NLRP10 lacks the LRR
region.

Absent in mouse

–

Absent in mouse

–

Comments: NLRP3 has also been reported to respond to
host-derived products, known as danger-associated molecular
patterns, or DAMPs, including uric acid [155], ATP, L-glucose,
hyaluronan and amyloid β (APP, P05067) [200].

Loss-of-function mutations of NLRP3 are associated with cold
autoinﬂammatory and Muckle-Wells syndromes.

protein (NAIP, Q13075) which can be found in the ’Inhibitors of
apoptosis (IAP) protein family’ in the Other protein targets
section of the Guide.

This family also includes NLR family, apoptosis inhibitory
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RIG-I-like receptor family

Catalytic receptors → Pattern recognition receptors → RIG-I-like receptor family
Overview: There are three human RIG-I-like receptors (RLRs) which are cytoplasmic pattern recognition receptors (PRRs) of the innate immune system. They detect non-self cytosolic double-stranded
RNA species and and 5’-triphosphate single-stranded RNA from various sources and are essential for inducing production of type I interferons, such as IFNβ, type III interferons, and other
anti-pathogenic effectors [23, 24]. They function as RNA helicases (EC 3.6.4.13) using the energy from ATP hydrolysis to unwind RNA.
Further reading on RIG-I-like receptor family
Chow KT et al. (2018) RIG-I and Other RNA Sensors in Antiviral Immunity. Annu Rev Immunol 36:
667-694 [PMID:29677479]
Kato H et al. (2015) RIG-I-like receptors and autoimmune diseases. Curr Opin Immunol 37: 40-5
[PMID:26530735]
Lässig C et al. (2017) Discrimination of cytosolic self and non-self RNA by RIG-I-like receptors.
J Biol Chem 292: 9000-9009 [PMID:28411239]

Ma Z et al. (2018) Innate Sensing of DNA Virus Genomes. Annu Rev Virol 5: 341-362
[PMID:30265633]
Yong HY et al. (2018) RIG-I-Like Receptors as Novel Targets for Pan-Antivirals and Vaccine
Adjuvants Against Emerging and Re-Emerging Viral Infections. Front Immunol 9: 1379
[PMID:29973930]

Nomenclature

DExD/H-box helicase 58

interferon induced with helicase C domain 1

DExH-box helicase 58

Common abbreviation

RIG-1

MDA5

LGP2

HGNC, UniProt

DDX58, O95786

IFIH1, Q9BYX4

DHX58, Q96C10

EC number

3.6.4.13
RNA helicase: uses the energy from ATP hydrolysis to unwind
RNA: ATP + H(2)O <=> ADP + phosphate

3.6.4.13
RNA helicase; uses the energy from ATP to unwind RNA: ATP +
H(2)O <=> ADP + phosphate

3.6.4.13
RNA helicase: uses the energy from ATP hydrolysis to
unwind RNA: ATP + H(2)O <=> ADP + phosphate

Receptor guanylyl cyclase (RGC) family
Catalytic receptors → Receptor guanylyl cyclase (RGC) family

Overview: The mammalian genome encodes seven guanylyl cyclases, GC-A to GC-G, that are homodimeric transmembrane receptors activated by a diverse range of endogenous ligands. These
enzymes convert guanosine-5’-triphosphate to the intracellular second messenger cyclic guanosine-3’,5’-monophosphate (cyclic GMP). GC-A, GC-B and GC-C are expressed predominantly in the
cardiovascular system, skeletal system and intestinal epithelium, respectively. GC-D and GC-G are found in the olfactory neuropepithelium and Grueneberg ganglion of rodents, respectively. GC-E and
GC-F are expressed in retinal photoreceptors.
Further reading on Receptor guanylyl cyclase (RGC) family
Kuhn M. (2016) Molecular Physiology of Membrane Guanylyl Cyclase Receptors. Physiol Rev 96:
751-804 [PMID:27030537]

Waldman SA et al. (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders.
Gut 67: 1543-1552 [PMID:29563144]
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Transmembrane guanylyl cyclases

Catalytic receptors → Receptor guanylyl cyclase (RGC) family → Transmembrane guanylyl cyclases
Overview: Transmembrane guanylyl cyclases are homodimeric
receptors activated by a diverse range of endogenous ligands.
GC-A, GC-B and GC-C are expressed predominantly in the
cardiovascular system, skeletal system and intestinal epithelium,
respectively. GC-D and GC-G are found in the olfactory

neuropepithelium and Grüeneberg ganglion of rodents,
respectively. GC-E and GC-F are expressed in retinal
photoreceptors. Family members have conserved ligand-binding,
catalytic (guanylyl cyclase) and regulatory domains with the
exception of NPR-C which has an extracellular binding domain

homologous to that of other NPRs, but with a truncated
intracellular domain which appears to couple, via the Gi/o family
of G proteins, to activation of phospholipase C,
inwardly-rectifying potassium channels and inhibition of
adenylyl cyclase activity [169].

Nomenclature

Guanylyl cyclase-A

Guanylyl cyclase-B

Guanylyl cyclase-C

natriuretic peptide receptor 3

Common abbreviation

GC-A

GC-B

GC-C

NPR-C

HGNC, UniProt

NPR1, P16066

NPR2, P20594

GUCY2C, P25092

Potency order

atrial natriuretic peptide (NPPA, P01160) ≥ brain C-type natriuretic peptide (NPPC, P23582) uroguanylin (GUCA2B, Q16661) >
natriuretic peptide (NPPB, P16860)  C-type
 atrial natriuretic peptide (NPPA,
guanylin (GUCA2A, Q02747)
natriuretic peptide (NPPC, P23582) [217]
P01160)  brain natriuretic peptide
(NPPB, P16860) [217]

atrial natriuretic peptide (NPPA, P01160) >
C-type natriuretic peptide (NPPC, P23582)
≥ brain natriuretic peptide (NPPB,
P16860) [217]

Endogenous agonists

atrial natriuretic peptide (NPPA, P01160)
(Binding) [181], brain natriuretic peptide (NPPB,
P16860) (Binding) [181], mutant ANP [158]

C-type natriuretic peptide (NPPC, P23582) guanylin (GUCA2A, Q02747) (Binding),
(Binding) [217]
uroguanylin (GUCA2B, Q16661) (Binding)

–

Selective agonists

Dendroaspis natriuretic peptide [208], PL-3994
[52], cenderitide [153], sANP [181]

cenderitide [153], vosoritide [143]

linaclotide [26, 86], E. coli heat-stable
enterotoxin (STa ) [26], plecanatide [204]

cANF4-23 [145]

NPR3, P17342

Endogenous antagonists

–

–

–

osteocrin (OSTN, P61366) [163]

Selective antagonists

A-71915 (pKi 9.2–9.5) [47],
[Asu7,23’]β-ANP-(7-28) (pKi 7.5) [112],
HS-142-1 [166], anantin [240, 250]

peptide P19 (pKd 7.8) [49], HS-142-1
[166], [Ser11 ](N-CNP,C-ANP)pBNP2-15
[49], compound C10 [8]

–

AP811 (Binding) (pKi 9.3) [232],
M372049 [97]

Labelled ligands

[125 I]ANP (human) (Agonist)

[125 I]CNP (human)

[125 I]Sta (Agonist) [84]

[125 I]ANP (human)
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Nomenclature

Guanylyl cyclase-D

Guanylyl cyclase-E

Guanylyl cyclase-F

Guanylyl cyclase-G

Common abbreviation

GC-D

GC-E

GC-F

GC-G

HGNC, UniProt

–

GUCY2D, Q02846

GUCY2F, P51841

GUCY2GP, –

Localisation

–

Retinal photoreceptors

Retinal photoreceptors

Grüneberg ganglion

Principal function(s)

–

Vision/phototransduction

Vision/phototransduction

Thermosensation

Endogenous ligands

–

–

–

Cold

Comments

Pseudogene in humans

–

–

Pseudogene in humans

Comments: GC-D and GC-G have been reported to be activated intracellularly by guanylyl cyclase-activating protein 1 (GUCA1A, P43080) and guanylyl cyclase-activating protein 2 (GUCA1B,
Q9UMX6). GC-D and GC-G may be activated by atmospheric levels of CO2 through the formation of intracellular bicarbonate ions [31, 98]. GC-G may be activated at cooler temperatures (20-25°C)
through apparent stabilisation of the dimer [30].

Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
Catalytic receptors → Receptor guanylyl cyclase (RGC) family → Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase

Overview: Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase (GTP diphosphate-lyase (cyclising)), E.C. 4.6.1.2, is a heterodimer comprising a β1 subunit and one of two alpha subunits (α1 , α2 ) giving
rise to two functionally indistinguishable isoforms, GC-1 (α1 β1 ) and GC-2 (α2 β1 ) [195, 258]. A haem group is associated with the β subunit and is the target for the endogenous ligand NO, and,
potentially, carbon monoxide [63].

Nomenclature

Guanylyl cyclase, α1 β1

Common abbreviation

GC-1

GC-2

Subunits

Guanylyl cyclase α1 subunit, Guanylyl cyclase β1 subunit

Guanylyl cyclase α2 subunit, Guanylyl cyclase β1 subunit

EC number

4.6.1.2

4.6.1.2

Endogenous ligands

NO

NO

Selective activators

praliciguat (pEC50 6.6) [223], YC-1 [63, 121, 195], cinaciguat [apo-GC-1] [213], olinciguat [27],
riociguat [211, 212]

YC-1 [121, 195], cinaciguat [apo-GC-2] [213], olinciguat [27], riociguat [211, 212]

Selective inhibitors

NS 2028 (pIC50 8.1) [179] – Bovine, ODQ (pIC50 7.5) [68]

ODQ
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Subunits

Nomenclature

Guanylyl cyclase α1 subunit

Guanylyl cyclase α2 subunit

Guanylyl cyclase β1 subunit

Guanylyl cyclase β2 subunit

HGNC, UniProt

GUCY1A1, Q02108

GUCY1A2, P33402

GUCY1B1, Q02153

GUCY1B2, O75343

Comments: ODQ also shows activity at other haem-containing proteins [58], while YC-1 may also inhibit cGMP-hydrolysing phosphodiesterases [62, 65].

Receptor tyrosine kinases (RTKs)

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs)
Overview: Receptor tyrosine kinases (RTKs), a family of
cell-surface receptors, which transduce signals to polypeptide
and protein hormones, cytokines and growth factors are key
regulators of critical cellular processes, such as proliferation and
differentiation, cell survival and metabolism, cell migration and
cell cycle control [16, 77, 230]. In the human genome, 58 RTKs
have been identiﬁed, which fall into 20 families [132].
All RTKs display an extracellular ligand binding domain, a single
transmembrane helix, a cytoplasmic region containing the
protein tyrosine kinase activity (occasionally split into two

domains by an insertion, termed the kinase insertion), with
juxta-membrane and C-terminal regulatory regions. Agonist
binding to the extracellular domain evokes dimerization, and
sometimes oligomerization, of RTKs (a small subset of RTKs
forms multimers even in the absence of activating ligand). This
leads to autophosphorylation in the tyrosine kinase domain in a
trans orientation, serving as a site of assembly of protein
complexes and stimulation of multiple signal transduction
pathways, including phospholipase C-γ, mitogen-activated
protein kinases and phosphatidylinositol 3-kinase [230].

RTKs are of widespread interest not only through physiological
functions, but also as drug targets in many types of cancer and
other disease states. Many diseases result from genetic changes or
abnormalities that either alter the activity, abundance, cellular
distribution and/or regulation of RTKs. Therefore, drugs that
modify the dysregulated functions of these RTKs have been
developed which fall into two categories. One group is often
described as ‘biologicals’, which block the activation of RTKs
directly or by chelating the cognate ligands, while the second are
small molecules designed to inhibit the tyrosine kinase activity
directly.

Further reading on Receptor tyrosine kinases (RTKs)
Álvarez-Aznar A et al. (2017) VEGF Receptor Tyrosine Kinases: Key Regulators of Vascular
Function. Curr Top Dev Biol 123: 433-482 [PMID:28236974]
Bergeron JJ et al. (2016) Spatial and Temporal Regulation of Receptor Tyrosine Kinase Activation
and Intracellular Signal Transduction. Annu Rev Biochem 85: 573-97 [PMID:27023845]
Carvalho S et al. (2016) Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of
anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol 173: 1407-24 [PMID:26833433]
De Silva DM et al. (2017) Targeting the hepatocyte growth factor/Met pathway in cancer. Biochem
Soc Trans 45: 855-870 [PMID:28673936]
Eklund L et al. (2017) Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems.
Clin Sci 131: 87-103 [PMID:27941161]
Katayama R. (2017) Therapeutic strategies and mechanisms of drug resistance in anaplastic
lymphoma kinase (ALK)-rearranged lung cancer. Pharmacol Ther 177: 1-8 [PMID:28185914]
Kazlauskas A. (2017) PDGFs and their receptors. Gene 614: 1-7 [PMID:28267575]
Ke EE et al. (2016) EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung
Cancer: Where Do We Stand Now? Trends Pharmacol Sci 37: 887-903 [PMID:27717507]

Kuwano M et al. (2016) Overcoming drug resistance to receptor tyrosine kinase inhibitors:
Learning from lung cancer. Pharmacol Ther 161: 97-110 [PMID:27000770]
Lee DH. (2017) Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a
success, paved with failures. Pharmacol Ther 174: 1-21 [PMID:28167215]
Nelson KN et al. (2017) Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic
Disorders. Trends Mol Med 23: 59-79 [PMID:27988109]
Simons M et al. (2016) Mechanisms and regulation of endothelial VEGF receptor signalling. Nat
Rev Mol Cell Biol 17: 611-25 [PMID:27461391]
Stricker S et al. (2017) ROR-Family Receptor Tyrosine Kinases. Curr Top Dev Biol 123: 105-142
[PMID:28236965]
Tan AC et al. (2017) Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug
Discov Today 22: 72-84 [PMID:27452454]
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Type I RTKs: ErbB (epidermal growth factor) receptor family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type I RTKs: ErbB (epidermal growth factor) receptor family
Overview: ErbB family receptors are Class I receptor tyrosine
kinases [77]. ERBB2 (also known as HER-2 or NEU) appears to act
as an essential partner for the other members of the family
without itself being activated by a cognate ligand [78]. Ligands
of the ErbB family of receptors are peptides, many of which are

generated by proteolytic cleavage of cell-surface proteins.
HER/ErbB is the viral counterpart to the receptor tyrosine kinase
EGFR. All family members heterodimerize with each other to
activate downstream signalling pathways and are aberrantly
expressed in many cancers, particularly forms of breast cancer

and lung cancer. Mutations in the EGFR are responsible for
acquired resistance to tyrosine kinase inhibitor
chemotherapeutics.

Further reading on Type I RTKs: ErbB (epidermal growth factor) receptor family
Kobayashi Y et al. (2016) Not all epidermal growth factor receptor mutations in lung cancer are
created equal: Perspectives for individualized treatment strategy. Cancer Sci 107: 1179-86
[PMID:27323238]

Nomenclature

epidermal growth factor receptor

erb-b2 receptor tyrosine kinase 2

erb-b2 receptor tyrosine kinase 3

erb-b2 receptor tyrosine kinase 4

Common abbreviation

EGFR

HER2

HER3

HER4

HGNC, UniProt

EGFR, P00533

ERBB2, P04626

ERBB3, P21860

ERBB4, Q15303

EC number

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

Endogenous ligands

EGF (EGF, P01133) (Binding), HB-EGF (HBEGF, Q99075) –
(Binding), TGFα (TGFA, P01135) (Binding),
amphiregulin (AREG, P15514) (Binding), betacellulin
(BTC, P35070) (Binding), epigen (EPGN, Q6UW88)
(Binding), epiregulin (EREG, O14944) (Binding)

neuregulin-1 (NRG1, Q02297),
neuregulin-2 (NRG2, O14511)

HB-EGF (HBEGF, Q99075), betacellulin (BTC,
P35070), epiregulin (EREG, O14944),
neuregulin-1 (NRG1, Q02297), neuregulin-2
(NRG2, O14511), neuregulin-3 (NRG3,
P56975), neuregulin-4 (NRG4, Q8WWG1)

Inhibitors

afatinib (pKd 9.6) [44], tesevatinib (pIC50 9.5) [70],
afatinib (pIC50 8–9.3) [39, 133]

poziotinib (pIC50 8.3) [172], CP-724714 –
(pIC50 7.9) [81], tesevatinib (pIC50 7.8)
[70], BMS-690514 (pIC50 7.7) [149]

poziotinib (pIC50 7.6) [172]

Antibodies

necitumumab (Binding) (pKd 9.5) [141], cetuximab
(Binding) (pKd 9.4) [73]

pertuzumab (Inhibition) (pIC50 >8)
[113], trastuzumab (Inhibition)

–

–

Comments: [125 I]EGF (human) has been used to label the ErbB1 EGF receptor. The extracellular domain of ErbB2 can be targetted by the antibodies trastuzumab and pertuzumab to inhibit ErbB family
action. The intracellular ATP-binding site of the tyrosine kinase domain can be inhibited by GW583340 (7.9-8.0, [69]), geﬁtinib, erlotinib and tyrphostins AG879 and AG1478.
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Type II RTKs: Insulin receptor family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type II RTKs: Insulin receptor family
Overview: The circulating peptide hormones insulin (INS,
P01308) and the related insulin-like growth factors (IGF) activate
Class II receptor tyrosine kinases [77], to evoke cellular responses,
mediated through multiple intracellular adaptor proteins.
Exceptionally amongst the catalytic receptors, the functional
receptor in the insulin receptor family is derived from a single
gene product, cleaved post-translationally into two peptides,

which then cross-link via disulphide bridges to form a
heterotetramer. Intriguingly, the endogenous peptide ligands are
formed in a parallel fashion with post-translational processing
producing a heterodimer linked by disulphide bridges. Signalling
through the receptors is mediated through a rapid
autophosphorylation event at intracellular tyrosine residues,
followed by recruitment of multiple adaptor proteins, notably

IRS1 (P35568), IRS2 (Q9Y4H2), SHC1 (P29353), GRB2 (P62993)
and SOS1 (Q07889).
Serum levels of free IGFs are kept low by the action of IGF
binding proteins (IGFBP1-5, P08833, P18065, P17936, P22692,
P24593), which sequester the IGFs; overexpression of IGFBPs
may induce apoptosis, while IGFBP levels are also altered in some
cancers.

Nomenclature

Insulin receptor

Insulin-like growth factor I receptor

Insulin receptor-related receptor

Common abbreviation

InsR

IGF1R

IRR

HGNC, UniProt

INSR, P06213

IGF1R, P08069

INSRR, P14616

EC number

2.7.10.1

2.7.10.1

2.7.10.1

Inhibitors

–

BMS-754807 (pIC50 8.7) [246], GSK-1838705A (pIC50 8.7) [197], GSK-1838705A (pKd 8.1) [44], PQ401 (pIC50 >6) [64],
AG 1024 (pIC50 4.7) [184]

–

Selective inhibitors

–

NVP-AEW541 (pIC50 9.4) [67]

–

Endogenous agonists

insulin (INS, P01308)

insulin-like growth factor 1 (IGF1, P05019), insulin-like growth factor 2 (IGF2, P01344)

–

Comments: There is evidence for low potency binding and
activation of insulin receptors by IGF1. IGF2 also binds and
activates the cation-independent mannose 6-phosphate receptor
(also known as the insulin-like growth factor 2 receptor; IGF2R;
P11717), which lacks classical signalling capacity and appears to
subserve a trafﬁcking role [146]. INSRR, which has a much more

discrete localization, being predominant in the kidney [124],
currently lacks a cognate ligand or evidence for functional
impact.

PQ401 inhibits the insulin-like growth factor receptor [5], while
BMS-536924 inhibits both the insulin receptor and the
insulin-like growth factor receptor [245].

Antibodies targetting IGF1, IGF2 and the extracellular portion of
the IGF1 receptor are in clinical trials.
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Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
Overview: Type III RTKs include PDGFR, CSF-1R (Ems), Kit and FLT3, which function as homo- or heterodimers. Endogenous ligands of PDGF receptors are homo- or heterodimeric: PDGFA, PDGFB,
VEGFE and PDGFD (PDGFD, Q9GZP0) combine as homo- or heterodimers to activate homo- or heterodimeric PDGF receptors. SCF is a dimeric ligand for KIT. Ligands for CSF1R are either monomeric or
dimeric glycoproteins, while the endogenous agonist for FLT3 is a homodimer.

Nomenclature

platelet derived growth factor receptor alpha

platelet derived growth factor receptor beta

KIT proto-oncogene, receptor tyrosine kinase

Common abbreviation

PDGFRα

PDGFRβ

Kit

HGNC, UniProt

PDGFRA, P16234

PDGFRB, P09619

KIT, P10721

EC number

2.7.10.1

2.7.10.1

2.7.10.1

Endogenous ligands

PDGF

PDGF

–

Inhibitors

PP121 (pIC50 8.7) [5], crenolanib (pKd 8.7)
[91], ENMD-2076 (pIC50 7.2) [187]

crenolanib (pKd 8.5) [91], SU-14813 (pIC50 8.4) [185],
famitinib (pIC50 8.4) [32], sunitinib (pIC50 8.2) [119],
sunitinib (pKi 8.1) [160]

sunitinib (pKd 9.4) [44], famitinib (pIC50 8.7) [32], masitinib
(pKd 8.1) [44], SU-14813 (pIC50 7.8) [185], AKN-028 (pIC50
7.5) [55], sorafenib (pIC50 7.2) [244]

Selective inhibitors

CP-673451 (pIC50 8) [193]

CP-673451 (pIC50 9) [193]

–

Endogenous agonists

–

–

stem cell factor (KITLG, P21583) [228]

Nomenclature

colony stimulating factor 1 receptor

fms related receptor tyrosine kinase 3

Common abbreviation

CSFR

FLT3

HGNC, UniProt

CSF1R, P07333

FLT3, P36888

EC number

2.7.10.1

2.7.10.1

Endogenous ligands

G-CSF (CSF3, P09919), GM-CSF (CSF2, P04141), M-CSF (CSF1, P09603)

Fms-related tyrosine kinase 3 ligand (FLT3LG, P49771)

Inhibitors

JNJ-28312141 (pIC50 9.2) [148], Ki-20227 (pKd 9.1) [44], Ki-20227 (pIC50 8.7) [178], GW-2580 (pKd 8.7) [44],
JNJ-28312141 (pKd 8.5) [44]

AC710 (pKd 9.3) [139], linifanib (pKd 9.2) [44], crenolanib
(pKd 9.1) [91], ENMD-2076 (pIC50 8.5) [187], tandutinib
(pKd 8.5) [44], tandutinib (pIC50 6.7) [115]

Selective inhibitors

GW-2580 (pIC50 7.2) [38]

G749 (pIC50 9.4) [129]

Comments

Upregulation of CSF1R expression is associated with migroglial activation and immune pathology in Alzhermer’s disease
(AD) [74, 75]. Pharmacological inhibition of CSF1R with GW-2580 reduces microglial proliferation and prevents disease
progression in a mouse model of AD, but this does not correlate with amyloid-β plaque numbers [180].

5’-ﬂuoroindirubinoxime has been described as a selective
FLT3 inhibitor [33].

Comments: Various small molecular inhibitors of type III RTKs have been described, including imatinib and nilotinib (targetting PDGFR, KIT and CSF1R); midostaurin and AC220 (quizartinib; FLT3),
as well as pan-type III RTK inhibitors such as sunitinib and sorafenib [186]; 5’-ﬂuoroindirubinoxime has been described as a selective FLT3 inhibitor [2].
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Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family
Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family
Overview: VEGF receptors are homo- and heterodimeric
proteins, which are characterized by seven Ig-like loops in their
extracellular domains and a split kinase domain in the
cytoplasmic region. They are key regulators of angiogenesis and
lymphangiogenesis; as such, they have been the focus of drug
discovery for conditions such as metastatic cancer. Splice

Nomenclature

variants of VEGFR1 and VEGFR2 generate truncated proteins
limited to the extracellular domains, capable of
homodimerisation and binding VEGF ligands as a soluble,
non-signalling entity. Ligands at VEGF receptors are typically
homodimeric. VEGFA (VEGFA, P15692) is able to activate
VEGFR1 homodimers, VEGFR1/2 heterodimers and VEGFR2/3

fms related receptor tyrosine kinase 1

heterodimers. VEGFB (VEGFB, P49765) and placental growth
factor (PGF, P49763) activate VEGFR1 homodimers, while
VEGFC (VEGFC, P49767) and VEGFD (VEGFD, O43915) activate
VEGFR2/3 heterodimers and VEGFR3 homodimers, and,
following proteolysis, VEGFR2 homodimers.

kinase insert domain receptor

fms related receptor tyrosine kinase 4

Common abbreviation

VEGFR-1

VEGFR-2

VEGFR-3

HGNC, UniProt

FLT1, P17948

KDR, P35968

FLT4, P35916

EC number

2.7.10.1

2.7.10.1

2.7.10.1

Endogenous ligands

VEGFA (VEGFA, P15692), VEGFB (VEGFB,
P49765)

VEGFA (VEGFA, P15692), VEGFC (VEGFC, P49767), VEGFE (PDGFC, Q9NRA1)

VEGFC (VEGFC, P49767), VEGFD (VEGFD, O43915),
VEGFE (PDGFC, Q9NRA1)

Inhibitors

SU-14813 (pIC50 8.7) [185], CEP-11981
(pIC50 8.5) [100], semaxanib (pIC50 8.1) [17]

cabozantinib (pIC50 10.5) [251], axitinib (pIC50 9.6) [130], foretinib (pIC50
8.2–9.1) [170], cediranib (pKd 9) [44], tesevatinib (pIC50 8.8) [70], motesanib
(pKd 8.6) [44], famitinib (pIC50 8.3) [32], axitinib (pKd 8.2) [44]

tesevatinib (pIC50 8.1) [70], sunitinib (pIC50 8.1)
[116], nintedanib (pIC50 7.9) [96]

Sub/family-selective
inhibitors

pazopanib (pIC50 8) [87]

pazopanib (pKd 7.8) [44], pazopanib (pIC50 7.5) [87]

pazopanib (pIC50 7.3) [87]

Antibodies

–

ramucirumab (Antagonist) (pIC50 9) [144]

–

Comments: The VEGFR, as well as VEGF ligands, have been targeted by antibodies and tyrosine kinase inhibitors. DMH4 [60], Ki8751 [123] and ZM323881, a novel inhibitor of vascular endothelial
growth factor-receptor-2 tyrosine kinase activity [242] are described as VEGFR2-selective tyrosine kinase inhibitors. Bevacizumab is a monoclonal antibody directed against VEGF-A, used clinically for
the treatment of certain metastatic cancers; an antibody fragment has been used for wet age-related macular degeneration.

Searchable database: http://www.guidetopharmacology.org/index.jsp
Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family S292
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.15541/full

S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2021/22: Catalytic receptors. British Journal of Pharmacology (2021) 178, S264-S312

Type V RTKs: FGF (ﬁbroblast growth factor) receptor family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type V RTKs: FGF (ﬁbroblast growth factor) receptor family
Overview: Fibroblast growth factor (FGF) family receptors act as
homo- and heterodimers, and are characterized by Ig-like loops
in the extracellular domain, in which disulphide bridges may
form across protein partners to allow the formation of covalent
dimers which may be constitutively active. FGF receptors have

been implicated in achondroplasia, angiogenesis and numerous
congenital disorders. At least 22 members of the FGF gene family
have been identiﬁed in the human genome [11]. Within this
group, subfamilies of FGF may be divided into canonical,
intracellular and hormone-like FGFs. FGF1-FGF10 have been

identiﬁed to act through FGF receptors, while FGF11-14 appear
to signal through intracellular targets. Other family members are
less well characterized [241].

Nomenclature

ﬁbroblast growth factor receptor 1

ﬁbroblast growth factor receptor 2

ﬁbroblast growth factor receptor 3

ﬁbroblast growth factor receptor 4

Common abbreviation

FGFR1

FGFR2

FGFR3

FGFR4

HGNC, UniProt

FGFR1, P11362

FGFR2, P21802

FGFR3, P22607

FGFR4, P22455

EC number

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

Endogenous ligands

FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-4 (FGF4, P08620) > FGF-5
(FGF5, P12034), FGF-6 (FGF6, P10767)
[183]

FGF-10 (FGF10, O15520) [255]
FGF-1 (FGF1, P05230) > FGF-4 (FGF4,
P08620), FGF-7 (FGF7, P21781), FGF-9
(FGF9, P31371) > FGF-2 (FGF2, P09038),
FGF-6 (FGF6, P10767) [183]

FGF-3 (FGF3, P11487)
FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-9 (FGF9, P31371) > FGF-4
(FGF4, P08620), FGF-8 (FGF8, P55075)
[183]

FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-4 (FGF4, P08620), FGF-9
(FGF9, P31371) > FGF-6 (FGF6, P10767),
FGF-8 (FGF8, P55075) [183]

Sub/family-selective inhibitors LY2874455 (pIC50 8.6) [260]

LY2874455 (pIC50 8.6) [260]

LY2874455 (pIC50 8.2) [260]

LY2874455 (pIC50 8.2) [260]

Selective inhibitors

–

–

–

BLU-9931 (Irreversible inhibition) (pIC50
8.5) [83]

Agonists

–

palifermin

–

–

Comments: Splice variation of the receptors can inﬂuence agonist responses. FGFRL1 (Q8N441) is a truncated kinase-null analogue.
Various antibodies and tyrosine kinase inhibitors have been developed against FGF receptors [136, 264]. PD161570 is an FGFR tyrosine kinase inhibitor [11], while PD173074 has been described to
inhibit FGFR1 and FGFR3 [209].
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Type VI RTKs: PTK7/CCK4

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type VI RTKs: PTK7/CCK4
Overview: The PTK7 receptor is associated with polarization of epithelial cells and the development of neural structures. Sequence analysis suggests that the gene product is catalytically inactive as a
protein kinase, although there is evidence for a role in Wnt signalling [190].

Nomenclature

protein tyrosine kinase 7 (inactive)

Common abbreviation

CCK4

HGNC, UniProt

PTK7, Q13308

EC number

2.7.10.1

Comments: Thus far, no selective PTK7 inhibitors have been described.

Type VII RTKs: Neurotrophin receptor/Trk family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type VII RTKs: Neurotrophin receptor/Trk family
Overview: The neurotrophin receptor family of RTKs include
trkA, trkB and trkC (tropomyosin-related kinase) receptors,
which respond to NGF, BDNF and neurotrophin-3, respectively.
They are associated primarily with proliferative and migration

effects in neural systems. Various isoforms of neurotrophin
receptors exist, including truncated forms of trkB and trkC,
which lack catalytic domains. p75 (TNFRSF16, also known as
nerve growth factor receptor), which has homologies with
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tumour necrosis factor receptors, lacks a tyrosine kinase domain,
but can signal via ceramide release and nuclear factor κB (NF-κB)
activation. Both trkA and trkB contain two leucine-rich regions
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Nomenclature

neurotrophic receptor tyrosine kinase 1

neurotrophic receptor tyrosine kinase 2

neurotrophic receptor tyrosine kinase 3

Common abbreviation

trkA

trkB

trkC

HGNC, UniProt

NTRK1, P04629

NTRK2, Q16620

NTRK3, Q16288

EC number

2.7.10.1

2.7.10.1

2.7.10.1

Endogenous ligands

NGF (NGF, P01138) > neurotrophin-3 (NTF3, P20783)

BDNF (BDNF, P23560), neurotrophin-4 (NTF4, P34130) >
neurotrophin-3 (NTF3, P20783)

neurotrophin-3 (NTF3, P20783)

Inhibitors

selitrectinib (pIC50 >9.3) [173], compound 2c (pIC50 8.9)
[237], milciclib (pIC50 7.3) [19], ONO-7579 [105]

ONO-7579 [105]

ONO-7579 [105]

AZD1332 (pIC50 >8.3) [7], GNF-5837 (pIC50 8.1) [2]

AZD1332 (pIC50 >8.3) [7], GNF-5837 (pIC50 8.1) [2]

Sub/family-selective inhibitors AZD1332 (pIC50 >8.3) [7], GNF-5837 (pIC50 8) [2]

Comments: [125 I]NGF (human) and [125 I]BDNF (human) have
been used to label the trkA and trkB receptor, respectively. p75
inﬂuences the binding of NGF (NGF, P01138) and
neurotrophin-3 (NTF3, P20783) to trkA. The ligand selectivity of
p75 appears to be dependent on the cell type; for example, in

sympathetic neurones, it binds neurotrophin-3 (NTF3, P20783)
with comparable afﬁnity to trkC [46].
Small molecule agonists of trkB have been described, including
LM22A4 [156], while ANA12 has been described as a

non-competitive antagonist of BDNF binding to trkB [29].
GNF5837 is a family-selective tyrosine kinase inhibitor [2], while
the tyrosine kinase activity of the trkA receptor can be inhibited
by GW441756 (pIC50 = 8.7, [248]) and tyrphostin AG879 [177].

Type VIII RTKs: ROR family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type VIII RTKs: ROR family
Overview: Members of the ROR family appear to be activated by ligands complexing with other cell-surface proteins. Thus, ROR1 and ROR2 appear to be activated by Wnt-5a (WNT5A, P41221)
binding to a Frizzled receptor thereby forming a cell-surface multiprotein complex [80].

Nomenclature

receptor tyrosine kinase like orphan receptor 1

receptor tyrosine kinase like orphan receptor 2

Common abbreviation

ROR1

ROR2

HGNC, UniProt

ROR1, Q01973

ROR2, Q01974

EC number

2.7.10.1

2.7.10.1
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Type IX RTKs: MuSK

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type IX RTKs: MuSK
Overview: The muscle-speciﬁc kinase MuSK is associated with the formation and organisation of the neuromuscular junction from the skeletal muscle side. Agrin (AGRN, O00468) forms a complex
with low-density lipoprotein receptor-related protein 4 (LRP4, O75096) to activate MuSK [117].

Nomenclature

muscle associated receptor tyrosine kinase

Common abbreviation

MuSK

HGNC, UniProt

MUSK, O15146

EC number

2.7.10.1

Comments: Thus far, no selective MuSK inhibitors have been described.

Type X RTKs: HGF (hepatocyte growth factor) receptor family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type X RTKs: HGF (hepatocyte growth factor) receptor family
Overview: HGF receptors regulate maturation of the liver in the embryo, as well as having roles in the adult, for example, in the innate immune system. HGF is synthesized as a single gene product,
which is post-translationally processed to yield a heterodimer linked by a disulphide bridge. The maturation of HGF is enhanced by a serine protease, HGF activating complex, and inhibited by
HGF-inhibitor 1 (SPINT1, O43278), a serine protease inhibitor. MST1, the ligand of RON, is two disulphide-linked peptide chains generated by proteolysis of a single gene product.

Nomenclature

MET proto-oncogene, receptor tyrosine kinase

macrophage stimulating 1 receptor

Common abbreviation

MET

Ron

HGNC, UniProt

MET, P08581

MST1R, Q04912

EC number

2.7.10.1

2.7.10.1

Endogenous ligands

hepatocyte growth factor (HGF, P14210)

macrophage stimulating protein 1 (MST1, P09603)

Inhibitors

capmatinib (pIC50 9.9) [142], SGX-523 (pKd 9.7) [44], cabozantinib (pIC50 8.9) [251]

BMS-777607 (pIC50 8.7) [201]

Selective inhibitors

SGX-523 (pIC50 8.4) [25]

–

Comments: PF04217903 is a selective Met tyrosine kinase inhibitor [40]. SU11274 is an inhibitor of the HGF receptor [198], with the possibility of further targets [6].
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Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family
Overview: Members of this RTK family represented a novel structural motif, when sequenced. The ligands for this family, growth arrest speciﬁc protein 6 (GAS6, Q14393) and protein S (PROS1,
P07225), are secreted plasma proteins which undergo vitamin K-dependent post-translational modiﬁcations generating carboxyglutamate-rich domains which are able to bind to negatively-charged
surfaces of apoptotic cells.

Nomenclature

AXL receptor tyrosine kinase

TYRO3 protein tyrosine kinase

MER proto-oncogene, tyrosine kinase

Common abbreviation

Axl

Tyro3

Mer

HGNC, UniProt

AXL, P30530

TYRO3, Q06418

MERTK, Q12866

EC number

2.7.10.1

2.7.10.1

2.7.10.1

Endogenous ligands

growth arrest speciﬁc protein 6 (GAS6, Q14393) [171],
protein S (PROS1, P07225) [216]

growth arrest speciﬁc protein 6 (GAS6, Q14393) [171],
protein S (PROS1, P07225) [216]

growth arrest speciﬁc protein 6 (GAS6, Q14393) [171]

Comments: AXL tyrosine kinase inhibitors have been described [164].

Type XII RTKs: TIE family of angiopoietin receptors

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XII RTKs: TIE family of angiopoietin receptors
Overview: The TIE family were initially associated with formation of blood vessels. Endogenous ligands are angiopoietin-1 (ANGPT1, Q15389), angiopoietin-2 (ANGPT2, O15123), and angiopoietin-4
(ANGPT4, Q9Y264). Angiopoietin-2 (ANGPT2, O15123) appears to act as an endogenous antagonist of angiopoietin-1 function.

Nomenclature

tyrosine kinase with immunoglobulin like and EGF like domains 1

TEK receptor tyrosine kinase

Common abbreviation

TIE1

TIE2

HGNC, UniProt

TIE1, P35590

TEK, Q02763

EC number

2.7.10.1

2.7.10.1

Endogenous ligands

–

angiopoietin-1 (ANGPT1, Q15389), angiopoietin-4 (ANGPT4, Q9Y264)
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Type XIII RTKs: Ephrin receptor family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XIII RTKs: Ephrin receptor family
Overview: Ephrin receptors are a family of 15 RTKs (the largest
family of RTKs) with two identiﬁed subfamilies (EphA and
EphB), which have a role in the regulation of neuronal
development, cell migration, patterning and angiogenesis. Their
ligands are membrane-associated proteins, thought to be

glycosylphosphatidylinositol-linked for EphA (ephrin-A1
(EFNA1, P20827) , ephrin-A2 (EFNA2, O43921), ephrin-A3
(EFNA3, P52797), ephrin-A4 (EFNA4, P52798) and ephrin-A5
(EFNA5, P52803)) and 1TM proteins for Ephrin B
(ENSFM00250000002014: ephrin-B1 (EFNB1, P98172), ephrin-B2

(EFNB2, P52799) and ephrin-B3 (EFNB3, Q15768)), although the
relationship between ligands and receptors has been
incompletely deﬁned.

Nomenclature

EPH receptor A1

EPH receptor A2

EPH receptor A3

EPH receptor A4

EPH receptor A5

EPH receptor A6

EPH receptor A7

Common abbreviation

EphA1

EphA2

EphA3

EphA4

EphA5

EphA6

EphA7

HGNC, UniProt

EPHA1, P21709

EPHA2, P29317

EPHA3, P29320

EPHA4, P54764

EPHA5, P54756

EPHA6, Q9UF33

EPHA7, Q15375

EC number

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

Nomenclature

EPH receptor A8

EPH receptor A10

EPH receptor B1

EPH receptor B2

EPH receptor B3

EPH receptor B4

EPH receptor B6

Common abbreviation

EphA8

EphA10

EphB1

EphB2

EphB3

EphB4

EphB6

HGNC, UniProt

EPHA8, P29322

EPHA10, Q5JZY3

EPHB1, P54762

EPHB2, P29323

EPHB3, P54753

EPHB4, P54760

EPHB6, O15197

EC number

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

2.7.10.1

Inhibitors

–

–

compound 66 (pIC50 9) [126]

–

–

tesevatinib (pIC50 8.9) [70]

–
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Type XIV RTKs: RET

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XIV RTKs: RET
Overview: Ret proto-oncogene (Rearranged during transfection) is a transmembrane tyrosine kinase enzyme which is employed as a signalling partner for members of the GDNF family receptors.
Ligand-activated GFR appears to recruit Ret as a dimer, leading to activation of further intracellular signalling pathways. Ret appears to be involved in neural crest development, while mutations may be
involved in multiple endocrine neoplasia, Hirschsprung’s disease, and medullary thyroid carcinoma.

Nomenclature

ret proto-oncogene

Common abbreviation

Ret

HGNC, UniProt

RET, P07949

EC number

2.7.10.1

Inhibitors

tamatinib (pIC50 8.3) [34]

Comments: A number of tyrosine kinase inhibitors targeting RET have been described [56].

Type XV RTKs: RYK

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XV RTKs: RYK
Overview: The ‘related to tyrosine kinase receptor’ (Ryk) is structurally atypical of the family of RTKs, particularly in the activation and ATP-binding domains. RYK has been suggested to lack kinase
activity and appears to be involved, with FZD8, in the Wnt signalling system [190].

Nomenclature

receptor like tyrosine kinase

Common abbreviation

RYK

HGNC, UniProt

RYK, P34925

EC number

2.7.10.1

Comments: Thus far, no selective RYK inhibitors have been described.
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Type XVI RTKs: DDR (collagen receptor) family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XVI RTKs: DDR (collagen receptor) family
Overview: Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are structurally-related membrane protein tyrosine kinases activated by collagen. Collagen is probably the most abundant protein in
man, with at least 29 families of genes encoding proteins, which undergo splice variation and post-translational processing, and may exist in monomeric or polymeric forms, producing a triple-stranded,
twine-like structure. In man, principal family members include COL1A1 (COL1A1, P02452), COL2A1 (COL2A1, P02458), COL3A1 (COL3A1, P02461) and COL4A1 (COL4A1, P02462).

Nomenclature

discoidin domain receptor tyrosine kinase 1

discoidin domain receptor tyrosine kinase 2

Common abbreviation

DDR1

DDR2

HGNC, UniProt

DDR1, Q08345

DDR2, Q16832

EC number

2.7.10.1

2.7.10.1

Comments: The tyrosine kinase inhibitors of DDR, imatinib and nilotinib, were identiﬁed from proteomic analysis [45]. Other collagen receptors include glycoprotein VI (Q9HCN6),
leukocyte-associated immunoglobulin-like receptor 1 (Q6GTX8), leukocyte-associated immunoglobulin-like receptor 2 (Q6ISS4) and osteoclast-associated immunoglobulin-like receptor (Q8IYS5).

Type XVII RTKs: ROS receptors

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XVII RTKs: ROS receptors
Overview: The ROS1 gene encodes a receptor tyrosine kinase, whose endogenous substrate and normal physiological functions are not fully determined. Aberrant expression and mutated forms of
ROS1 are drivers of malignant transformation in number of tumour types.

Nomenclature

c-ros oncogene 1, receptor tyrosine kinase

Common abbreviation

ROS

HGNC, UniProt

ROS1, P08922

EC number

2.7.10.1

Comments: Crizotinib is a tyrosine kinase inhibitor, anti-cancer drug targeting ALK and ROS1.
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Type XVIII RTKs: LMR family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XVIII RTKs: LMR family
Overview: The LMR kinases are unusual amongst the RTKs in possessing a short extracellular domain and extended intracellular domain (hence the ‘Lemur’ name reﬂecting the long tail). A precise
function for these receptors has yet to be deﬁned, although LMR1 was identiﬁed as a potential marker of apoptosis [66], giving rise to the name AATYK (Apoptosis-associated tyrosine kinase); while
over-expression induces differentiation in neuroblastoma cells [192].

Nomenclature

apoptosis associated tyrosine kinase

lemur tyrosine kinase 2

lemur tyrosine kinase 3

Common abbreviation

Lmr1

Lmr2

Lmr3

HGNC, UniProt

AATK, Q6ZMQ8

LMTK2, Q8IWU2

LMTK3, Q96Q04

EC number

2.7.11.1

2.7.11.1

2.7.11.1

Comments: As yet no selective inhibitors of the LMR family have been described.

Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family
Overview: The LTK family appear to lack endogenous ligands. LTK is subject to tissue-speciﬁc splice variation, which appears to generate products in distinct subcellular locations. ALK fusions created
by gene translocations and rearrangements are associated with many types of cancer, including large cell lymphomas, inﬂammatory myoﬁbrilastic tumours and non-small cell lung cancer [152].
Further reading on Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family
Orthofer M et al. (2020) Identiﬁcation of ALK in Thinness Cell

Nomenclature

leukocyte receptor tyrosine kinase ALK receptor tyrosine kinase

Common abbreviation LTK

ALK

HGNC, UniProt

LTK, P29376

ALK, Q9UM73

EC number

2.7.10.1

2.7.10.1

Inhibitors

–

GSK-1838705A (pIC50 9.3) [197], compound 8e (pIC50 9.1) [99], crizotinib (pIC50 9) [41], NVP-TAE684 (pKd 9) [44], compound 25b (pIC50 8.7) [72]

Selective inhibitors

–

ceritinib (pIC50 9.7) [152]

Comments

–

Crizotinib appears to be a selective ALK inhibitor acting on the tyrosine kinase activity [71]
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Type XX RTKs: STYK1

Catalytic receptors → Receptor kinases → TK: Tyrosine kinase → Receptor tyrosine kinases (RTKs) → Type XX RTKs: STYK1
Overview: Similar to the LMR RTK family, STYK1 has a truncated extracellular domain, but also displays a relatively short intracellular tail beyond the split kinase domain. STYK1 (also known as Novel
Oncogene with Kinase-domain, NOK) has been suggested to co-localize with activated EGF receptor [50].

Nomenclature

serine/threonine/tyrosine kinase 1

Common abbreviation

STYK1

HGNC, UniProt

STYK1, Q6J9G0

EC number

2.7.10.2

Comments: As yet, no selective inhibitors of STYK1 have been described.

Receptor serine/threonine kinase (RSTK) family
Catalytic receptors → Receptor kinases → TKL: Tyrosine kinase-like → Receptor serine/threonine kinase (RSTK) family
Overview: Receptor serine/threonine kinases (RSTK), EC
2.7.11.30, respond to particular cytokines, the transforming
growth factor β (TGFβ) and bone morphogenetic protein (BMP)
families, and may be divided into two subfamilies on the basis of
structural similarities. Agonist binding initiates formation of a
cell-surface complex of type I and type II RSTK, possibly
heterotetrameric, where both subunits express serine/threonine
kinase activity. The type I receptor serine/threonine kinases are
also known as activin receptors or activin receptor-like kinases,
ALKs, for which a systematic nomenclature has been proposed
(ALK1-7). The type II protein phosphorylates the kinase domain
of the type I partner (sometimes referred to as the signal
propagating subunit), causing displacement of the protein

partners, such as the FKBP12 FK506-binding protein FKBP1A
(P62942) and allowing the binding and phosphorylation of
particular members of the Smad family. These migrate to the
nucleus and act as complexes to regulate gene transcription.
Type III receptors, sometimes called co-receptors or accessory
proteins, regulate the signalling of the receptor complex, in
either enhancing (for example, presenting the ligand to the
receptor) or inhibitory manners. TGFβ family ligand signalling
may be inhibited by endogenous proteins, such as follistatin
(FST, P19883), which binds and neutralizes activins to prevent
activation of the target receptors.
Endogenous agonists, approximately 30 in man, are often

described as paracrine messengers acting close to the source of
production. They are characterized by six conserved cysteine
residues and are divided into two subfamilies on the basis of
sequence comparison and signalling pathways activated, the
TGFβ/activin/nodal subfamily and the BMP/GDF
(growth/differentiation factor)/MIS (Müllerian inhibiting
substance) subfamily. Ligands active at RSTKs appear to be
generated as large precursors which undergo complex
maturation processes [135]. Some are known to form
disulphide-linked homo- and/or heterodimeric complexes. Thus,
inhibins are α subunits linked to a variety of β chains, while
activins are combinations of β subunits.

Further reading on Receptor serine/threonine kinase (RSTK) family
Budi EH et al. (2017) Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity
and Functional Versatility. Trends Cell Biol 27: 658-672 [PMID:28552280]
Chen W et al. (2016) Immunoregulation by members of the TGFβ superfamily. Nat Rev Immunol
16: 723-740 [PMID:27885276]
Heger J et al. (2016) Molecular switches under TGFβ signalling during progression from cardiac
hypertrophy to heart failure. Br J Pharmacol 173: 3-14 [PMID:26431212]
Luo JY et al. (2015) Regulators and effectors of bone morphogenetic protein signalling in the
cardiovascular system. J Physiol (Lond.) 593: 2995-3011 [PMID:25952563]

Macias MJ et al. (2015) Structural determinants of Smad function in TGF-β signaling. Trends
Biochem Sci 40: 296-308 [PMID:25935112]
Morrell NW et al. (2016) Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev
Cardiol 13: 106-20 [PMID:26461965]
Neuzillet C et al. (2015) Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther 147:
22-31 [PMID:25444759]
van der Kraan PM. (2017) The changing role of TGFβ in healthy, ageing and osteoarthritic joints.
Nat Rev Rheumatol 13: 155-163 [PMID:28148919]
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Type I receptor serine/threonine kinases

Catalytic receptors → Receptor kinases → TKL: Tyrosine kinase-like → Receptor serine/threonine kinase (RSTK) family → Type I receptor serine/threonine kinases
Overview: The type I receptor serine/threonine kinases are also known as activin receptors or activin receptor-like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1-7).
Further reading on Type I receptor serine/threonine kinases
Batlle E et al. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity
50: 924-940 [PMID:30995507]

Nomenclature

activin A
receptor type IL

activin A receptor
type 1

bone morphogenetic
protein receptor type IA

activin A receptor type 1B

transforming growth factor beta
receptor 1

bone morphogenetic
protein receptor type IB

activin A receptor
type 1C

Common abbreviation

ALK1

ALK2

BMPR1A

ALK4

TGFBR1

BMPR1B

ALK7

HGNC, UniProt

ACVRL1, P37023

ACVR1, Q04771

BMPR1A, P36894

ACVR1B, P36896

TGFBR1, P36897

BMPR1B, O00238

ACVR1C, Q8NER5

EC number

2.7.11.30

2.7.11.30

2.7.11.30

2.7.11.30

2.7.11.30

2.7.11.30

2.7.11.30

Inhibitors

–

ML347 (pIC50 7.5)
[54]

–

–

LY2109761 (pKi 7.4) [159],
compound 15b (pIC50 7.1) [134]

–

–

Selective inhibitors

–

–

–

vactosertib (pIC50 7.9) [110] vactosertib (pIC50 8) [110]

–

–
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Type II receptor serine/threonine kinases

Catalytic receptors → Receptor kinases → TKL: Tyrosine kinase-like → Receptor serine/threonine kinase (RSTK) family → Type II receptor serine/threonine kinases
Overview: The type II protein phosphorylates the kinase domain of the type I partner (sometimes referred to as the signal propagating subunit), causing displacement of the protein partners, such as
the FKBP12 FK506-binding protein FKBP1A (P62942) and allowing the binding and phosphorylation of particular members of the Smad family.
Further reading on Type II receptor serine/threonine kinases
Batlle E et al. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity
50: 924-940 [PMID:30995507]

Nomenclature

activin A receptor type 2A

activin A receptor type 2B

anti-Mullerian hormone receptor bone morphogenetic protein
type 2
receptor type 2

transforming growth factor beta
receptor 2

Common abbreviation

ActR2

ActR2B

MISR2

BMPR2

TGFBR2

HGNC, UniProt

ACVR2A, P27037

ACVR2B, Q13705

AMHR2, Q16671

BMPR2, Q13873

TGFBR2, P37173

EC number

2.7.11.30

2.7.11.30

2.7.11.30

2.7.11.30

2.7.11.30

Antibodies

–

bimagrumab (Binding) (pKd 11.8) [12]

–

–

–

Type III receptor serine/threonine kinases

Catalytic receptors → Receptor kinases → TKL: Tyrosine kinase-like → Receptor serine/threonine kinase (RSTK) family → Type III receptor serine/threonine kinases
Overview: Type III receptors, sometimes called co-receptors or accessory proteins, regulate (enhance or inhibit) the signalling of the RSTK complex.

Nomenclature

transforming growth factor beta receptor 3

Common abbreviation

TGFBR3

HGNC, UniProt

TGFBR3, Q03167
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RSTK functional heteromers

Catalytic receptors → Receptor kinases → TKL: Tyrosine kinase-like → Receptor serine/threonine kinase (RSTK) family → RSTK functional heteromers
Overview: For the receptors listed on this page, the exact combination of subunits forming the functional heteromeric receptors is unknown.
Further reading on RSTK functional heteromers
Batlle E et al. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity
50: 924-940 [PMID:30995507]

Nomenclature

Transforming growth factor β receptor

Bone morphogenetic protein receptors

Subunits

transforming growth factor beta receptor 1 (Type I),
transforming growth factor beta receptor 2 (Type II),
transforming growth factor beta receptor 3 (Type III)

bone morphogenetic protein receptor type IA (Type I), bone morphogenetic protein receptor type IB (Type I), activin A receptor
type 1 (Type I), activin A receptor type IL (Type I), bone morphogenetic protein receptor type 2 (Type II), activin A receptor type
2A (Type II), activin A receptor type 2B (Type II)

Coupling

Smad2, Smad3 [168, 207]

Smad1, Smad5, Smad8 [168, 207]

Endogenous agonists TGFβ1 (TGFB1, P01137), TGFβ2 (TGFB2, P61812), TGFβ3 BMP-10 (BMP10, O95393), BMP-2 (BMP2, P12643), BMP-4 (BMP4, P12644), BMP-5 (BMP5, P22003), BMP-6 (BMP6, P22004),
(TGFB3, P10600)
BMP-7 (BMP7, P18075), BMP-8A (BMP8A, Q7Z5Y6), BMP-8B (BMP8B, P34820), BMP-9 (GDF2, Q9UK05)

Nomenclature

Growth/differentiation factor receptors

Activin receptors

Anti-Müllerian hormone receptors

Subunits

bone morphogenetic protein receptor type IA (Type I), bone morphogenetic
protein receptor type IB (Type I), activin A receptor type 1B (Type I), activin A
receptor type 1C (Type I), transforming growth factor beta receptor 1 (Type I),
bone morphogenetic protein receptor type 2 (Type II), activin A receptor type
2A (Type II), activin A receptor type 2B (Type II)

activin A receptor type 1B (Type I), activin A receptor
type 1C (Type I), activin A receptor type 2A (Type II),
activin A receptor type 2B (Type II)

bone morphogenetic protein receptor type IA
(Type I), bone morphogenetic protein receptor
type IB (Type I), activin A receptor type 1 (Type
I), anti-Mullerian hormone receptor type 2
(Type II)

Coupling

Smad1, Smad5, Smad8 [168, 207]

Smad2, Smad3 [207]

Smad1, Smad5, Smad8 [168, 207]

Endogenous agonists

growth/differentiation factor-1 (GDF1, P27539), growth/differentiation
activin A (INHBA, P08476), activin AB (INHBA INHBB,
factor-10 (GDF10, P55107), growth/differentiation factor-3 (GDF3, Q9NR23),
P08476 P09529), activin B (INHBB, P09529), inhibin A
growth/differentiation factor-7 (GDF7, Q7Z4P5), growth/differentiation factor-9 (INHA INHBA, P05111 P08476)
(GDF9, O60383)

Müllerian inhibiting substance (AMH, P03971)

Comments

–

–

Activin receptors are heteromeric complexes
comprising activin receptor type I and type II subunits.

Comments on Receptor serine/threonine kinase (RSTK) family: A number of endogenous inhibitory ligands have been identiﬁed for RSTKs, including BMP-3 (BMP3, P12645), inhibin α (INHA,
P05111), inhibin βC (INHBC, P55103) and inhibin βE (INHBE, P58166).
An appraisal of small molecule inhibitors of TGFβ and BMP signalling concluded that TGFβ pathway inhibitors were more selective than BMP signalling inhibitors [234]. The authors conﬁrmed the
selectivity of TGF-beta RI inhibitor III to inhibit TGFβ signalling through ALK4, ALK5, ALK7 [42]. Dorsomorphin inhibits BMP signalling through ALK2 and ALK3, it also inhibits AMP kinase [262].
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Smads were identiﬁed as mammalian orthologues of Drosophila genes termed “mothers against decapentaplegic” and may be divided into Receptor-regulated Smads (R-Smads, including Smad1,
Smad2, Smad3, Smad5 and Smad8), Co-mediated Smad (Co-Smad, Smad4) and Inhibitory Smads (I-Smad, Smad6 and Smad7). R-Smads form heteromeric complexes with Co-Smad. I-Smads compete for
binding of R-Smad with both receptors and Co-Smad.
Nomenclature

HGNC gene symbol

Uniprot ID

Other names

Smad1

SMAD1

Q15797

JV4-1, MADH1, MADR1

Smad2

SMAD2

Q15796

JV18-1, MADH2, MADR2

Smad3

SMAD3

P84022

HsT17436, JV15-2, MADH3

Smad4

SMAD4

Q13485

DPC4, MADH4

Smad5

SMAD5

Q99717

Dwfc, JV5-1, MADH5

Smad6

SMAD6

O43541

HsT17432, MADH6, MADH7

Smad7

SMAD7

O15105

MADH7, MADH8

Smad8

SMAD9

O15198

MADH6, MADH9

Receptor tyrosine phosphatase (RTP) family
Catalytic receptors → Receptor tyrosine phosphatase (RTP) family

Overview: Receptor tyrosine phosphatases (RTP) are cell-surface proteins with a single TM region and intracellular phosphotyrosine phosphatase activity. Many family members exhibit constitutive
activity in heterologous expression, dephosphorylating intracellular targets such as Src tyrosine kinase (SRC) to activate signalling cascades. Family members bind components of the extracellular matrix
or cell-surface proteins indicating a role in intercellular communication.
Further reading on Receptor tyrosine phosphatase (RTP) family
Papadimitriou E et al. (2016) Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta
as regulators of angiogenesis and cancer. Biochim Biophys Acta 1866: 252-265
[PMID:27693125]

Nomenclature

RTP Type A

RTP Type B

HGNC, UniProt

PTPRA, P18433

Putative endogenous ligands

–

Inhibitors

–

Stanford SM et al. (2017) Targeting Tyrosine Phosphatases: Time to End the Stigma. Trends
Pharmacol Sci 38: 524-540 [PMID:28412041]

RTP Type C

RTP Type D

RTP Type E

RTP Type F

RTP Type G

PTPRB, P23467

PTPRC, P08575

PTPRD, P23468

PTPRE, P23469

PTPRF, P10586

PTPRG, P23470

–

galectin-1 (LGALS1, netrin-G3 ligand
–
P09382) [235]
(LRRC4B, Q9NT99)
[125]

netrin-G3 ligand (LRRC4B,
Q9NT99) [125]

contactin-3 (CNTN3, Q9P232),
contactin-4 (CNTN4, Q8IWV2),
contactin-5 (CNTN5, O94779),
contactin-6 (CNTN6, Q9UQ52) [18]

–

–

illudalic acid (pIC50 5.9) [138]

compound 1 (pKi 5.6) [206]

–
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Nomenclature

RTP Type H

RTP Type J

RTP Type K

RTP Type M

RTP Type N

RTP Type N2

HGNC, UniProt

PTPRH, Q9HD43

PTPRJ, Q12913

PTPRK, Q15262

PTPRM, P28827

PTPRN, Q16849

PTPRN2, Q92932 PTPRO, Q16827

Putative endogenous ligands

–

–

galectin-3 (LGALS3, P17931), galectin-3
binding protein (LGALS3BP, Q08380) [118]

–

–

–

–

Inhibitors

–

–

–

compound 8a (pIC50 5.2) [89]

–

–

–

Nomenclature

RTP Type Q

RTP Type R

RTP Type S

RTP Type T

RTP Type U

RTP Type Z1

HGNC, UniProt

PTPRQ, Q9UMZ3

PTPRR, Q15256

PTPRS, Q13332

PTPRT, O14522

PTPRU, Q92729

PTPRZ1, P23471

Putative endogenous ligands

–

–

chondroitin sulphate proteoglycan 3 (NCAN, O14594),
netrin-G3 ligand (LRRC4B, Q9NT99) [125, 205]

–

–

contactin-1 (CNTN1, Q12860), pleiotrophin
(PTN, C9JR52) (acts as a negative regulator)
[18, 161]

Inhibitors

–

–

compound 7b (pIC50 5.4) [82], 7-BIA (pIC50 4.4) [229] –

–

–
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Tumour necrosis factor (TNF) receptor family
Catalytic receptors → Tumour necrosis factor (TNF) receptor family

Overview: Dysregulated TNFR signalling is associated with many inﬂammatory disorders, including some forms of arthritis and inﬂammatory bowel disease, and targeting TNF has been an effective
therapeutic strategy in these diseases and for cancer immunotherapy [21, 22, 203].
Further reading on Tumour necrosis factor (TNF) receptor family
Olesen CM et al. (2016) Mechanisms behind efﬁcacy of tumor necrosis factor inhibitors in
inﬂammatory bowel diseases. Pharmacol Ther 159: 110-9 [PMID:26808166]
von Karstedt S et al. (2017) Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer 17: 352-366 [PMID:28536452]

Blaser H et al. (2016) TNF and ROS Crosstalk in Inﬂammation. Trends Cell Biol 26: 249-261
[PMID:26791157]
Croft M et al. (2017) Beyond TNF: TNF superfamily cytokines as targets for the treatment of
rheumatic diseases. Nat Rev Rheumatol 13: 217-233 [PMID:28275260]
Kalliolias GD et al. (2016) TNF biology, pathogenic mechanisms and emerging therapeutic
strategies. Nat Rev Rheumatol 12: 49-62 [PMID:26656660]

Nomenclature

tumor necrosis
factor receptor 1

tumor necrosis
factor receptor 2

lymphotoxin β
receptor

OX40

CD40

Fas

decoy receptor 3

Systematic nomenclature

TNFRSF1A

TNFRSF1B

TNFRSF3

TNFRSF4

TNFRSF5

TNFRSF6

TNFRSF6B

Common abbreviation

TNFR1

TNFR2

–

–

–

–

–

HGNC, UniProt

TNFRSF1A, P19438

TNFRSF1B, P20333

LTBR, P36941

TNFRSF4, P43489

CD40, P25942

FAS, P25445

TNFRSF6B, O95407

Adaptor proteins

TRADD

TRAF1, TRAF2,
TRAF5

TRAF3, TRAF4,
TRAF5

TRAF1, TRAF2, TRAF3, TRAF5

TRAF1, TRAF2,
TRAF3, TRAF5,
TRAF6

FADD

–

Endogenous ligands

lymphotoxin-α
(LTA, P01374),
tumour necrosis
factor membrane
form (TNF,
P01375), tumour
necrosis factor shed
form (TNF, P01375)

lymphotoxin-α
(LTA, P01374),
tumour necrosis
factor membrane
form (TNF, P01375)

LIGHT (TNFSF14,
O43557),
lymphotoxin β2 α1
heterotrimer (LTA
LTB, P01374
Q06643)

OX-40 ligand (TNFSF4, P23510)

CD40 ligand
(CD40LG, P29965)

Fas ligand (FASLG,
P48023)

–

Ligands

–

–

–

compound 1 (Binding) (pIC50 5.9) [210]

–

–

–

Comments

–

–

–

The OX40/OX40L pair is involved in late T-cell
costimulatory signaling and both are
transiently expressed following antigen
recognition, and blocking OX40/OX40L is
reported to prevent the development of
disease in in vivo autoimmune and
inﬂammatory disease models [239]

–

–

Decoy receptor for
LIGHT (TNFSF14,
O43557), TL1A
(TNFSF15, O95150)
and Fas ligand
(FASLG, P48023).
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Nomenclature

CD27

CD30

4-1BB

death receptor 4

death receptor 5

decoy receptor 1

decoy receptor 2

Systematic nomenclature

TNFRSF7

TNFRSF8

TNFRSF9

TNFRSF10A

TNFRSF10B

TNFRSF10C

TNFRSF10D

Common abbreviation

–

–

–

DR4

DR5

–

–

HGNC, UniProt

CD27, P26842

TNFRSF8, P28908

TNFRSF9, Q07011

TNFRSF10A, O00220

TNFRSF10B, O14763

TNFRSF10C, O14798

TNFRSF10D, Q9UBN6

Adaptor proteins

TRAF2, SIVA

TRAF1, TRAF2, TRAF3,
TRAF5

TRAF1, TRAF2, TRAF3

FADD

FADD

–

–

Endogenous ligands

CD70 (CD70, P32970)

CD30 ligand (TNFSF8,
P32971)

4-1BB ligand (TNFSF9,
P41273)

TRAIL (TNFSF10,
P50591)

–

–

–

Endogenous agonists

–

–

–

–

TRAIL (TNFSF10,
P50591) [263]

–

–

Agonists

–

–

–

SC-67655 [85]

–

–

–

Antibodies

–

brentuximab vedotin
(Inhibition)

–

–

tigatuzumab (Agonist)
(pKd ∼8.5) [263]

–

–

Comments

–

–

–

–

–

Decoy receptor for TRAIL
(TNFSF10, P50591).

Decoy receptor for TRAIL
(TNFSF10, P50591).

Nomenclature

receptor activator of
NF-kappa B

osteoprotegerin

death receptor 3

TWEAK receptor

TACI

BAFF receptor

herpes virus entry mediator
TNFRSF14

Systematic nomenclature

TNFRSF11A

TNFRSF11B

TNFRSF25

TNFRSF12A

TNFRSF13B

TNFRSF13C

Common abbreviation

RANK

OPG

DR3

–

–

BAFF-R

HVEM

HGNC, UniProt

TNFRSF11A, Q9Y6Q6

TNFRSF11B, O00300

TNFRSF25, Q93038

TNFRSF12A, Q9NP84

TNFRSF13B, O14836

TNFRSF13C, Q96RJ3

TNFRSF14, Q92956

Adaptor proteins

TRAF1, TRAF2, TRAF3, –
TRAF5, TRAF6

TRADD

TRAF1, TRAF2, TRAF3

TRAF2, TRAF5, TRAF6

TRAF3

TRAF2, TRAF3, TRAF5

Endogenous ligands

RANK ligand
(TNFSF11, O14788)

–

TL1A (TNFSF15,
O95150)

TWEAK (TNFSF12,
O43508)

APRIL (TNFSF13,
O75888), BAFF
(TNFSF13B, Q9Y275)

BAFF (TNFSF13B,
Q9Y275)

B and T lymphocyte
attenuator (BTLA, Q7Z6A9),
LIGHT (TNFSF14, O43557),
lymphotoxin-α (LTA, P01374)

Comments

–

Acts as a decoy receptor for
RANK ligand (TNFSF11,
O14788) and possibly for
TRAIL (TNFSF10, P50591).

The only known
TNFSF ligand for DR3
is TNF-like protein 1A
(TL1A) [236].

–

–

–

–
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Nomenclature

nerve growth factor receptor

B cell maturation
antigen

glucocorticoid-induced
TNF receptor

toxicity and JNK
inducer

RELT

death receptor 6

Systematic nomenclature

TNFRSF16

TNFRSF17

TNFRSF18

TNFRSF19

TNFRSF19L

TNFRSF21
DR6

Common abbreviation

–

BCMA

GITR

TAJ

–

HGNC, UniProt

NGFR, P08138

TNFRSF17, Q02223

TNFRSF18, Q9Y5U5

TNFRSF19, Q9NS68

RELT, Q969Z4

TNFRSF21, O75509

Adaptor proteins

TRAF2, TRAF4, TRAF6

TRAF1, TRAF2,
TRAF3, TRAF5, TRAF6

TRAF1, TRAF2, TRAF3,
SIVA

TRAF1, TRAF2,
TRAF3, TRAF5

TRAF1

TRADD

Endogenous ligands

NGF (NGF, P01138) (pIC50 6) [108], BDNF
(BDNF, P23560), neurotrophin-3 (NTF3,
P20783), neurotrophin-4 (NTF4, P34130)

APRIL (TNFSF13,
O75888), BAFF
(TNFSF13B, Q9Y275)

TL6 (TNFSF18, Q9UNG2)

lymphotoxin-α (LTA,
P01374)

–

–

Comments

One of the two receptor types for the
neurotrophins (factors that stimulate neuronal
cell survival and differentiation). The other
family of neurotrophin receptors are the Trk
family of receptor tyrosine kinases.

–

–

Believed to be
essential during
embryonic
development.

Abundant in hematologic
tissues. Selective receptor for
TNF receptor-associated
factor 1 (TRAF1). Activates
the NF-κB pathway.

–

Nomenclature

TNFRSF22

TNFRSF23

ectodysplasin A2 isoform receptor

ectodysplasin 1, anhidrotic receptor

Systematic nomenclature

–

–

TNFRS27

–

HGNC, UniProt

–

–

EDA2R, Q9HAV5

EDAR, Q9UNE0

Adaptor proteins

–

–

TRAF1, TRAF3, TRAF6

TRAF1, TRAF2, TRAF3

Endogenous ligands

–

–

ectodysplasin A2 (EDA, Q92838) [252]

ectodysplasin A1 (EDA, Q92838) [252]

Comments

Only identiﬁed in mouse to date. A potential
decoy receptor for the cytotoxic ligand
TNFSF10/TRAIL. Does not contain a
cytoplasmic death domain so does not induce
apoptosis, and does not activate the NF-κB
signalling pathway.

Only identiﬁed in mouse to date. A potential
decoy receptor for the cytotoxic ligand
TNFSF10/TRAIL. Does not contain a
cytoplasmic death domain so does not induce
apoptosis, and does not activate the NF-κB
signalling pathway.

Receptor for the EDA-A2 isoform of
ectodysplasin encoded by the anhidrotic
ectodermal dysplasia (EDA) gene.

Cell surface receptor for ectodysplasin A
(a morphogen involved in the
development of ectodermal tissues,
including skin, hair, nails, teeth, and
sweat glands).

Comments: TNFRSF1A is preferentially activated by the shed
form of TNF ligand, whereas the membrane-bound form of TNF
serves to activate TNFRSF1A and TNFRSF1B equally. The
neurotrophins nerve growth factor (NGF (NGF, P01138)),
brain-derived neurotrophic factor (BDNF (BDNF, P23560)),

neurotrophin-3 (NTF3, P20783) (NTF3) and neurotrophin-4
(NTF4, P34130) (NTF4) are structurally unrelated to the TNF
ligand superfamily but exert some of their actions through the
“low afﬁnity nerve growth factor receptor” (NGFR (TNFRSF16))
as well as through the TRK family of receptor tyrosine kinases.
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The endogenous ligands for EDAR and EDA2R are, respectively,
the membrane (Q92838[1-391]) and secreted (Q92838[160-391])
isoforms of Ectodysplasin-A (EDA, Q92838).
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